

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission File Number 001-31812

**ANI PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**58-2301143**  
(IRS Employer  
Identification Number)

**210 Main Street West**  
**Baudette, Minnesota 56623**  
(Address of principal executive offices)

**(218) 634-3500**

(Registrant's telephone number including area code)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class:</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered:</u>
Common Stock	ANIP	Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of October 31, 2025 there were 22,458,168 shares of common stock and 10,864 shares of class C special stock of the registrant outstanding.

**ANI PHARMACEUTICALS, INC.**  
**FORM 10-Q — Quarterly Report**  
**For the Quarterly Period Ended September 30, 2025**

	<u>Page</u>	
<b><u>PART I—FINANCIAL INFORMATION</u></b>		
<a href="#">Item 1.</a>	<a href="#">Condensed Consolidated Financial Statements (unaudited)</a>	5
	<a href="#">Condensed Consolidated Balance Sheets (unaudited) — As of September 30, 2025 and December 31, 2024</a>	6
	<a href="#">Condensed Consolidated Statements of Operations (unaudited) — For the Three and Nine Months Ended September 30, 2025 and 2024</a>	7
	<a href="#">Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) — For the Three and Nine Months Ended September 30, 2025 and 2024</a>	8
	<a href="#">Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity (unaudited) — For the Three and Nine Months Ended September 30, 2025 and 2024</a>	9
	<a href="#">Condensed Consolidated Statements of Cash Flows (unaudited) — For the Nine Months Ended September 30, 2025 and 2024</a>	11
	<a href="#">Notes to Condensed Consolidated Financial Statements (unaudited)</a>	13
<a href="#">Item 2.</a>	<a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	45
<a href="#">Item 3.</a>	<a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	60
<a href="#">Item 4.</a>	<a href="#">Controls and Procedures</a>	60
<b><u>PART II—OTHER INFORMATION</u></b>		
<a href="#">Item 1.</a>	<a href="#">Legal Proceedings</a>	61
<a href="#">Item 1A.</a>	<a href="#">Risk Factors</a>	61
<a href="#">Item 2.</a>	<a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>	61
<a href="#">Item 3.</a>	<a href="#">Defaults upon Senior Securities</a>	61
<a href="#">Item 4.</a>	<a href="#">Mine Safety Disclosures</a>	61
<a href="#">Item 5.</a>	<a href="#">Other Information</a>	61
<a href="#">Item 6.</a>	<a href="#">Exhibits</a>	62
<a href="#">Signatures</a>		63

## CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

*This Quarterly Report on Form 10-Q and certain information incorporated herein by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such statements include, but are not limited to, statements about future operations, strategies and growth potential, the revenue potential (licensing, royalty and sales) of products we sell, development timelines, expected timeframe for submission of new drug applications, abbreviated new drug applications, or supplemental new drug applications to the U.S. Food and Drug Administration (the "FDA"), pipeline or potential markets for our products, selling and marketing strategies and associated costs to support the sales of Purified Cortrophin® Gel (Repository Corticotropin Injection USP) ("Cortrophin Gel"), the acquisition and integration of Alimera Sciences, Inc. ("Alimera"), the impact of accounting principles, litigation expenses, liquidity and capital resources, the potential impact of new legislation, including the One Big Beautiful Bill Act (the "Act"), the impact of global pandemics on our business, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words, and the use of future dates. Such forward-looking statements are based on the reasonable beliefs of our management as well as assumptions made by and information currently available to our management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified; therefore, our actual results may differ materially from those described in any forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in our periodic reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including those discussed in the "Risk Factors" section in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 which are summarized below:*

- Our approved products, including Cortrophin Gel, ILUVIEN and YUTIQ, may not achieve commercialization at levels of market acceptance that will continue to allow us to achieve profitability;
- We may fail to realize the benefits expected from our acquisition of Alimera and the combined company may not perform as we or the market expects;
- The limited number of suppliers for our API could result in lengthy delays in production if we need to change suppliers;
- Several of the products we have acquired cannot be manufactured in our facilities and we must secure and maintain qualified and compliant contract manufacturers. Noncompliance by these contract manufacturers or our inability to find qualified contract manufacturers could result in us being unable to commercialize these products; several of our products are manufactured and/or packaged by single-sourced third parties, which we cannot control and could result in us being unable to market and distribute products;
- We are subject to United States federal and state laws related to healthcare fraud and abuse and health information privacy and security, and the failure to comply with such laws may adversely affect our business;
- Failure to comply with data protection laws and regulations could subject us to government enforcement actions, private litigation and/or adverse publicity, which could negatively affect our operating results and business;
- Our Medicaid rebate accruals have increased and continue to increase due to our acquisitions and subsequent sales of branded products and authorized generics of branded products;
- Our accruals for the Medicare Coverage Gap Discount Program have increased due to growth and acquisitions;
- We expect to spend a significant amount of resources on research and development efforts, and such efforts may not result in marketable products;
- Production at any or all of our three current manufacturing facilities could be interrupted, which could cause us to fail to deliver product on a timely basis;
- We rely on third parties to assist with our clinical trials. If these parties do not perform or are non-compliant, it could negatively impact the clinical trial and potential of regulatory approval; further, we may be required to audit or redo previously completed trials or recall already-approved commercial products;
- Clinical trials for our products may not generate the outcomes we expect, may take longer or be more costly to complete than we anticipate;
- We may be adversely affected by the expiration of patents that protect key aspects of our products in the near- to medium-term;
- Inability to protect our intellectual property in the U.S. and foreign countries could negatively affect sales of our branded products;
- If we fail to comply with our obligations in the agreements under which we license development or commercialization rights to products or technology from third parties, we could lose license rights that are material to our business;
- Our success is largely dependent upon certain key employees, including members of our senior management, the loss of whom could adversely affect our operations;
- We rely significantly on information technology and any failure, inadequacy, interruption, or security lapse of that technology could harm our ability to operate the business effectively;
- We are involved in and may become involved in legal proceedings from time to time, which may result in substantial losses, government enforcement actions, damage to our business and reputation, and place a strain on our internal resources;
- We are susceptible to product liability claims that may not be covered by insurance, which, if successful, could require us to pay substantial sums;

- The obligations and liabilities of Alimera, some of which may be unanticipated or unknown, may be greater than we have anticipated, which may diminish the value of Alimera to us;
- Our operations in an international market subject us to additional regulatory oversight both in the international market and in the U.S., as well as social, and political uncertainties, which could cause a material adverse effect on our business, financial position, and operating results;
- Our operations, including those resulting from our acquisition of Alimera, and its international operations, will subject us to political and economic risks, increase our exposure to potential liability under anti-corruption, trade protection, tax, and other laws and regulations;
- Future acquisitions and investments could disrupt our business and harm our financial position and operating results;
- Pharmaceutical product quality standards are steadily increasing on all products, and if we cannot meet these standards, we may be required to discontinue marketing and/or recall products from the market;
- Federal and state false claims litigation brought against us by private individuals and the government could result in civil and criminal penalties, damages, fines and other related actions;
- The use of legal, regulatory, and legislative strategies by competitors could result in increased costs to develop and market our products, delay new product introductions and reduce profit potential;
- Third-party payer actions may prevent us from effectively marketing our products or cause us to decrease pricing;
- Healthcare reform legislation could have a material adverse effect on our business, financial position, and operating results;
- Public health outbreaks, epidemics, or pandemics (such as COVID-19) have adversely affected and may in the future adversely affect our business;
- The continuing trend toward consolidation of customer groups could result in declines in the sales volume and prices of our products, and increased fees charged by customers;
- The U.S. Food and Drug Administration (“FDA”) does not provide guidance on safety labeling for products that are marketed without approved New Drug Applications (“NDAs”) or Abbreviated New Drug Applications (“ANDAs”), which could increase our potential liability with respect to failure-to-warn claims for these products;
- Four of our products are marketed without approved NDAs or ANDAs and we can offer no assurances that the FDA will not require us to either seek approval for these products or withdraw them from the market. In either case, our business, financial position, and operating results could be materially adversely affected;
- If the Drug Enforcement Administration (“DEA”) does not approve supply of the API we need to manufacture our controlled substances, we may be unable to manufacture controlled substances, which would eliminate our revenue on these products;
- Our policies regarding returns, allowances and chargebacks, and marketing programs adopted by wholesalers may reduce revenues in future fiscal periods;
- Our indebtedness and liabilities could limit the cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operation;
- To service our indebtedness, we will be required to generate a significant amount of cash;
- Our New Credit Agreement contains restrictive and financial covenants and if we are not in compliance with these covenants, our outstanding indebtedness under this facility could be accelerated and the lenders could terminate their commitments under the facility;
- We incurred certain risks relating to our 2.25% Convertible Senior Notes due 2029 and related capped call transactions; and
- Raising additional funds by issuing additional equity securities may cause dilution to our current stockholders; raising additional funds by entering into additional credit or other borrowing facilities or issuing debt may subject us to covenants and other requirements that may restrict our operations.

*These factors should not be construed as exhaustive and should be read in conjunction with our other disclosures, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2024, including the factors described in “Item 1A. Risk Factors.” Other risks may be described from time to time in our filings made under the securities laws, including our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. New risks emerge from time to time. It is not possible for our management to predict all risks. The forward-looking statements contained in this document are made only as of the date of this document. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.*

*The Company may use its investor relations website as a distribution channel of material company information. Financial and other important information regarding the Company is routinely posted on and accessible through the Company’s investor relations website. We encourage investors and others interested in our Company to review the information we post on our investor relations website in addition to filings with the SEC, press releases, public conference calls and webcasts. Information contained on the Company’s website is not included as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.*

**Part I — FINANCIAL INFORMATION**

**Item 1. Condensed Consolidated Financial Statements (unaudited)**

**ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Balance Sheets**  
*(in thousands, except share and per share amounts)*  
*(unaudited)*

<b>Assets</b>	<b>September 30, 2025</b>	<b>December 31, 2024</b>
<b>Current Assets</b>		
Cash and cash equivalents	\$ 262,610	\$ 144,861
Restricted cash	36	33
Accounts receivable, net of \$125,165 and \$127,824 of adjustments for chargebacks and other allowances at September 30, 2025 and December 31, 2024, respectively	252,617	221,726
Inventories	146,475	136,782
Prepaid income taxes	9,254	—
Prepaid expenses and other current assets	18,551	17,975
Investment in equity securities	8,859	6,307
Total Current Assets	<u>698,402</u>	<u>527,684</u>
<b>Non-current Assets</b>		
Property and equipment, net	63,560	56,863
Deferred tax assets, net of deferred tax liabilities and valuation allowance	71,396	85,106
Intangible assets, net	499,817	541,834
Goodwill	62,480	59,990
Derivatives and other non-current assets	12,497	12,220
Total Assets	<u>\$ 1,408,152</u>	<u>\$ 1,283,697</u>
<b>Liabilities, Mezzanine Equity, and Stockholders' Equity</b>		
<b>Current Liabilities</b>		
Current debt, net of deferred financing costs	\$ 15,241	\$ 9,172
Accounts payable	69,795	45,656
Accrued royalties	51,247	22,626
Accrued compensation and related expenses	33,221	37,725
Accrued government rebates	37,032	18,714
Income taxes payable	—	6,749
Returned goods reserve	50,005	39,274
Current contingent consideration	63	29
Accrued expenses and other	13,951	13,735
Total Current Liabilities	<u>270,555</u>	<u>193,680</u>
<b>Non-current Liabilities</b>		
Non-current debt, net of deferred financing costs and current component	297,677	309,108
Non-current convertible notes, net of deferred financing costs	307,392	305,812
Non-current contingent consideration, net of current	11,379	19,825
Accrued licensor payments due	4,062	20,961
Other non-current liabilities	11,270	5,781
Total Liabilities	<u>\$ 902,335</u>	<u>\$ 855,167</u>
Commitments and Contingencies (Note 15)		
<b>Mezzanine Equity</b>		
Convertible Preferred Stock, Series A, \$0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at September 30, 2025 and 25,000 shares issued and outstanding at December 31, 2024	—	24,850
<b>Stockholders' Equity</b>		
Common Stock, \$0.0001 par value, 66,000,000 shares authorized; 23,076,007 shares issued and 22,462,035 outstanding at September 30, 2025; \$0.0001 par value, 33,333,334 shares authorized 21,537,707 shares issued and 21,108,152 shares outstanding at December 31, 2024	3	2
Class C Special Stock, \$0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	—	—
Preferred Stock, \$0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	—	—
Treasury stock, 613,972 shares of common stock, at cost, at September 30, 2025 and 429,555 shares of common stock, at cost, at December 31, 2024	(32,638)	(21,040)
Additional paid-in capital	586,230	519,653
Accumulated deficit	(50,589)	(100,279)
Accumulated other comprehensive income, net of tax	2,811	5,344
Total Stockholders' Equity	<u>505,817</u>	<u>403,680</u>
Total Liabilities, Mezzanine Equity, and Stockholders' Equity	<u>\$ 1,408,152</u>	<u>\$ 1,283,697</u>

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Operations**  
*(in thousands, except per share amounts)*  
*(unaudited)*

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Net Revenues	\$ 227,813	\$ 148,332	\$ 636,306	\$ 423,802
<b>Operating Expenses</b>				
Cost of sales (excluding depreciation and amortization)	93,389	63,075	241,041	169,930
Research and development	12,304	10,128	39,403	27,935
Selling, general, and administrative	76,656	79,075	234,955	179,917
Depreciation and amortization	22,632	15,748	68,804	45,131
Contingent consideration fair value adjustment	(14,470)	825	(25,285)	1,274
Loss (gain) on disposal of assets	295	—	295	(5,347)
Intangible asset impairment charge	767	—	767	—
<b>Total Operating Expenses, net</b>	<b>191,573</b>	<b>168,851</b>	<b>559,980</b>	<b>418,840</b>
Operating income (loss)	36,240	(20,519)	76,326	4,962
<b>Other Expense, net</b>				
Unrealized gain on investment in equity securities	3,140	1,355	2,551	8,298
Interest expense, net	(4,727)	(2,331)	(15,649)	(11,587)
Other (expense) income, net	(853)	(2,535)	1,084	(2,655)
Loss on extinguishment of debt	—	(7,468)	—	(7,468)
<b>Income (Loss) Before Income Tax Expense (Benefit)</b>	<b>33,800</b>	<b>(31,498)</b>	<b>64,312</b>	<b>(8,450)</b>
Income tax expense (benefit)	7,183	(7,332)	13,465	(204)
<b>Net Income (Loss)</b>	<b>\$ 26,617</b>	<b>\$ (24,166)</b>	<b>\$ 50,847</b>	<b>\$ (8,246)</b>
Dividends on Series A Convertible Preferred Stock	(344)	(406)	(1,157)	(1,219)
<b>Net Income (Loss) Available to Common Shareholders</b>	<b>\$ 26,273</b>	<b>\$ (24,572)</b>	<b>\$ 49,690</b>	<b>\$ (9,465)</b>
<b>Basic and Diluted Income (Loss) Per Share:</b>				
Basic Income (Loss) Per Share	\$ 1.19	\$ (1.27)	\$ 2.26	\$ (0.49)
Diluted Income (Loss) Per Share	\$ 1.13	\$ (1.27)	\$ 2.15	\$ (0.49)
Basic Weighted-Average Shares Outstanding	20,074	19,404	19,840	19,275
Diluted Weighted-Average Shares Outstanding	21,093	19,404	20,911	19,275

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Comprehensive Income (Loss)**  
*(in thousands)*  
*(unaudited)*

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Net Income (Loss)	\$ 26,617	\$ (24,166)	\$ 50,847	\$ (8,246)
Other comprehensive loss, net of tax:				
Foreign currency translation adjustment	429	(100)	967	(209)
Loss on interest rate swap	(930)	(2,862)	(3,500)	(3,282)
Total other comprehensive loss, net of tax	(501)	(2,962)	(2,533)	(3,491)
Total comprehensive income (loss), net of tax	<u>\$ 26,116</u>	<u>\$ (27,128)</u>	<u>\$ 48,314</u>	<u>\$ (11,737)</u>

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity**  
**For the Three Months Ended September 30, 2025 and 2024**  
*(in thousands)*  
*(unaudited)*

	Mezzanine Equity Series A Convertible Preferred Stock	Mezzanine Equity Series A Convertible Preferred Stock Shares	Common Stock Par Value	Common Stock Shares	Class C Special Stock	Additional Paid-in Capital	Treasury Stock Shares	Treasury Stock	Accumulated Other Comprehensive Income, Net of Tax	Accumulated Deficit	Total Mezzanine Equity and Stockholders' Equity
Balance, June 30, 2024	\$ 24,850	25	\$ 2	21,476	\$ —	\$ 532,497	413	\$ (20,042)	\$ 8,328	\$ (65,025)	\$ 480,610
Stock-based Compensation Expense	—	—	—	—	—	7,484	—	—	—	—	7,484
Capped Call Transactions, net of tax	—	—	—	—	—	(30,275)	—	—	—	—	(30,275)
Treasury Stock Purchases for Restricted Stock Vests	—	—	—	—	—	—	11	(680)	—	—	(680)
Issuance of Common Shares upon Stock Option and ESPP Exercise	—	—	—	3	—	1,193	—	—	—	—	1,193
Issuance of Restricted Stock Awards	—	—	—	62	—	—	—	—	—	—	—
Restricted Stock Awards Forfeitures	—	—	—	(47)	—	—	—	—	—	—	—
Dividends on Series A Convertible Preferred Stock	—	—	—	—	—	—	—	—	—	(406)	(406)
Other Comprehensive Loss	—	—	—	—	—	—	—	—	(2,962)	—	(2,962)
Net Loss	—	—	—	—	—	—	—	—	—	(24,166)	(24,166)
Balance, September 30, 2024	\$ 24,850	25	\$ 2	21,494	\$ —	\$ 510,899	424	\$ (20,722)	\$ 5,366	\$ (89,597)	\$ 430,798
Balance, June 30, 2025	\$ 24,850	25	\$ 2	22,322	\$ —	\$ 541,899	602	\$ (31,594)	\$ 3,312	\$ (76,862)	\$ 461,607
Stock-based Compensation Expense	—	—	—	—	—	9,691	—	—	—	—	9,691
Treasury Stock Purchases for Restricted Stock Vests	—	—	—	—	—	—	12	(1,044)	—	—	(1,044)
Issuance of Common Shares upon Stock Option and ESPP Exercise	—	—	—	152	—	9,790	—	—	—	—	9,790
Issuance of Restricted Stock Awards	—	—	—	36	—	—	—	—	—	—	—
Restricted Stock Awards Forfeitures	—	—	—	(37)	—	—	—	—	—	—	—
Conversion of Series A Convertible Preferred Stock	(24,850)	(25)	1	603	—	24,850	—	—	—	—	1
Dividends on Series A Convertible Preferred Stock	—	—	—	—	—	—	—	—	—	(344)	(344)
Other Comprehensive Loss	—	—	—	—	—	—	—	—	(501)	—	(501)
Net Income	—	—	—	—	—	—	—	—	—	26,617	26,617
Balance, September 30, 2025	\$ —	—	\$ 3	23,076	\$ —	\$ 586,230	614	\$ (32,638)	\$ 2,811	\$ (50,589)	\$ 505,817

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity**  
**For the Nine Months Ended September 30, 2025 and 2024**  
*(in thousands)*  
*(unaudited)*

	Mezzanine Equity Series A Convertible Preferred Stock	Mezzanine Equity Series A Convertible Preferred Stock Shares	Common Stock Par Value	Common Stock Shares	Class C Special Stock	Additional Paid-in Capital	Treasury Stock Shares	Treasury Stock	Accumulated Other Comprehensive Income, Net of Tax	Accumulated Deficit	Total Mezzanine Equity and Stockholders' Equity
Balance, December 31, 2023	\$ 24,850	25	\$ 2	20,731	\$ —	\$ 514,103	264	\$ (10,081)	\$ 8,857	\$ (80,132)	\$ 457,599
Stock-based Compensation Expense	—	—	—	—	—	22,283	—	—	—	—	22,283
Capped Call Transactions, net of tax	—	—	—	—	—	(30,275)	—	—	—	—	(30,275)
Treasury Stock Purchases for Restricted Stock Vests	—	—	—	—	—	—	160	(10,641)	—	—	(10,641)
Issuance of Common Shares upon Stock Option and ESPP Exercise	—	—	—	80	—	4,788	—	—	—	—	4,788
Issuance of Restricted Stock Awards	—	—	—	669	—	—	—	—	—	—	—
Issuance of Performance Stock Units	—	—	—	74	—	—	—	—	—	—	—
Restricted Stock Awards Forfeitures	—	—	—	(60)	—	—	—	—	—	—	—
Dividends on Series A Convertible Preferred Stock	—	—	—	—	—	—	—	—	—	(1,219)	(1,219)
Other Comprehensive Loss	—	—	—	—	—	—	—	—	(3,491)	—	(3,491)
Net Loss	—	—	—	—	—	—	—	—	—	(8,246)	(8,246)
Balance, September 30, 2024	\$ 24,850	25	\$ 2	21,494	\$ —	\$ 510,899	424	\$ (20,722)	\$ 5,366	\$ (89,597)	\$ 430,798
Balance, December 31, 2024	\$ 24,850	25	\$ 2	21,538	\$ —	\$ 519,653	430	\$ (21,040)	\$ 5,344	\$ (100,279)	\$ 428,530
Stock-based Compensation Expense	—	—	—	—	—	28,161	—	—	—	—	28,161
Treasury Stock Purchases for Restricted Stock Vests	—	—	—	—	—	—	184	(11,598)	—	—	(11,598)
Issuance of Common Shares upon Stock Option and ESPP Exercise	—	—	—	228	—	13,566	—	—	—	—	13,566
Issuance of Restricted Stock Awards	—	—	—	710	—	—	—	—	—	—	—
Issuance of Performance Stock Units	—	—	—	80	—	—	—	—	—	—	—
Restricted Stock Awards Forfeitures	—	—	—	(83)	—	—	—	—	—	—	—
Conversion of Series A Convertible Preferred Stock	(24,850)	(25)	1	603	—	24,850	—	—	—	—	1
Dividends on Series A Convertible Preferred Stock	—	—	—	—	—	—	—	—	—	(1,157)	(1,157)
Other Comprehensive Loss	—	—	—	—	—	—	—	—	(2,533)	—	(2,533)
Net Income	—	—	—	—	—	—	—	—	—	50,847	50,847
Balance, September 30, 2025	\$ —	—	\$ 3	23,076	\$ —	\$ 586,230	614	\$ (32,638)	\$ 2,811	\$ (50,589)	\$ 505,817

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Cash Flows**  
*(in thousands)*  
*(unaudited)*

	<b>Nine Months Ended September 30,</b>	
	<b>2025</b>	<b>2024</b>
<b>Cash Flows From Operating Activities</b>		
Net income (loss)	\$ 50,847	\$ (8,246)
Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities:		
Stock-based compensation	28,161	22,283
Deferred taxes	11,881	(4,383)
Depreciation and amortization	68,804	45,131
Unrealized gain on investment in equity securities	(2,551)	(8,298)
Non-cash operating lease expense	1,204	1,134
Non-cash interest	1,005	319
Contingent consideration fair value adjustment	(25,285)	1,274
Loss (gain) on disposal of assets	295	(5,347)
Loss on debt extinguishment	—	7,468
Amortization of inventory step up	—	3,224
Asset impairment charges	767	—
Changes in operating assets and liabilities:		
Accounts receivable, net	(30,674)	4,426
Inventories	(9,693)	(20,612)
Prepaid expenses and other assets	(564)	3,822
Accounts payable	22,391	7,300
Accrued royalties	28,621	7,171
Income taxes	(16,003)	(14,268)
Accrued government rebates	18,318	(1,475)
Returned goods reserve	10,731	4,296
Accrued expenses, accrued compensation, and other	(3,397)	2,938
<b>Net Cash and Cash Equivalents Provided by Operating Activities</b>	<b>154,858</b>	<b>48,157</b>
<b>Cash Flows From Investing Activities</b>		
Acquisition of Alimera, net of cash acquired	—	(393,079)
Acquisition of product rights, intangible assets, and other related assets	(20,327)	(631)
Acquisition of property and equipment, net	(12,591)	(13,842)
Proceeds from the sale of building	—	13,514
<b>Net Cash and Cash Equivalents Used in Investing Activities</b>	<b>(32,918)</b>	<b>(394,038)</b>
<b>Cash Flows From Financing Activities</b>		
Proceeds from convertible notes	—	316,250
Proceeds from term loan	—	325,000
Purchase of capped call transaction	—	(40,575)
Repayment on borrowings under credit agreement	—	(292,500)
Debt issuance costs	—	(15,376)
Principal payments on borrowings	(6,093)	(1,500)
Series A convertible preferred stock dividends paid	(1,157)	(1,219)
Proceeds from stock option exercises and ESPP purchases	13,566	4,788
Treasury stock purchases for restricted stock vests	(11,598)	(10,641)
Payments on contingent consideration	(26)	(12,500)
Payment of accrued licensor payments	—	(1,875)
<b>Net Cash and Cash Equivalents (Used in) Provided by Financing Activities</b>	<b>(5,308)</b>	<b>269,852</b>
<b>Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</b>	<b>1,120</b>	<b>(75)</b>
<b>Net Change in Cash, Cash Equivalents, and Restricted Cash</b>	<b>117,752</b>	<b>(76,104)</b>
<b>Cash, cash equivalents, and restricted cash, beginning of period</b>	<b>144,894</b>	<b>221,121</b>
<b>Cash, cash equivalents, and restricted cash end of period</b>	<b>\$ 262,646</b>	<b>\$ 145,017</b>

	Nine Months Ended September 30,	
	2025	2024
<b>Reconciliation of cash, cash equivalents, and restricted cash, beginning of period</b>		
Cash and cash equivalents	\$ 144,861	\$ 221,121
Restricted cash	33	—
<b>Cash, cash equivalents, and restricted cash, beginning of period</b>	<b>\$ 144,894</b>	<b>\$ 221,121</b>
<b>Reconciliation of cash, cash equivalents, and restricted cash, end of period</b>		
Cash and cash equivalents	\$ 262,610	\$ 144,982
Restricted cash	36	35
<b>Cash, cash equivalents, and restricted cash, end of period</b>	<b>\$ 262,646</b>	<b>\$ 145,017</b>
<b>Supplemental disclosure for cash flow information:</b>		
Cash paid for interest, net of amounts capitalized	\$ 22,318	\$ 19,232
Cash paid for income taxes	\$ 16,613	\$ 17,214
<b>Supplemental non-cash investing and financing activities:</b>		
Conversion of convertible preferred stock into common stock	\$ 24,850	\$ —
Right of use assets obtained in exchange for new operating lease liabilities	\$ 5,244	\$ —
Property and equipment purchased and included in accounts payable	\$ 1,029	\$ 635
Purchase consideration for Alimera Acquisition	\$ —	\$ (16,523)
Accrued deferred financing costs	\$ —	\$ (1,976)

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(Tabular Dollars in Thousands, Except Share and per Share Data)**  
**(Unaudited)**

**1. BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS**

**Overview**

ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, "ANI," the "Company," "we," "us," or "our") is a diversified bio-pharmaceutical company. The Company's mission is "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands business.

On September 16, 2024, the Company completed its previously announced acquisition of Alimera Sciences, Inc. ("Alimera"), a Delaware corporation, pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 21, 2024, by and among the Company, Alimera and ANIP Merger Sub INC., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub merged with and into Alimera, with Alimera surviving the merger as a wholly owned subsidiary of the Company. In connection with the acquisition, the Company added two new products, ILUVIEN® ("ILUVIEN") and YUTIQ® ("YUTIQ"). See Note 3 "Business Combination" in the notes to the condensed consolidated financial statements (unaudited) for further information on the acquisition.

During March 2025, the Company expanded the label for ILUVIEN to include an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye ("NIU-PS") in addition to the then current indication of Diabetic Macular Edema ("DME"). The Company is currently marketing ILUVIEN for both indications in the U.S. ILUVIEN was already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries. During the second quarter of 2025, the Company transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN with its combined label of DME and NIU-PS.

The Company owns and operates three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, and are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company ceased operations at the Oakville, Ontario, manufacturing location as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium Pharma LLC ("Novitium") in November 2021. The Company has fully completed the transition of the products manufactured or packaged at Oakville to one of the three U.S. based manufacturing sites. In February 2024, the Company entered into an agreement for the sale of the Oakville site, for a price of \$19.2 million Canadian Dollars, or approximately \$14.2 million, based on the exchange rate at closing of such transaction. The sale closed on March 28, 2024.

The Company held its 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") on May 22, 2025. At the 2025 Annual Meeting, the stockholders of the Company approved the amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 33.3 million shares to 66.0 million shares.

**Basis of Presentation**

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company's financial position, results of operations, comprehensive income (loss), and cash flows. The consolidated balance sheet at December 31, 2024 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the "SEC"). Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and notes thereto previously distributed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Form 10-K"), as filed with the SEC.

**Principles of Consolidation**

The unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

## Foreign Currency

The Company currently has subsidiaries located in Canada, India, Ireland, Germany, and the United Kingdom. The India-based subsidiary generally conducts its transactions in Indian Rupees, which is also its functional currency. The Ireland and Germany locations generally conduct their transactions in Euros, which is also their functional currency. The United Kingdom subsidiary conducts its transactions in Euros and British Pounds, and their functional currency is Euros. The Canada-based subsidiary conducts its transactions in U.S. dollars and Canadian dollars, but its functional currency is the U.S. dollar.

The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net (loss) income. Unless otherwise noted, all references to “\$” or “dollar” refer to the U.S. dollar. The Company’s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholders’ equity accounts, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company’s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders’ equity within accumulated other comprehensive income (loss), net of tax. Foreign currency transaction gains and losses include fluctuations related to long-term intercompany loans. Translation gains and losses on intercompany balances of a long-term investment nature are included in foreign currency translation adjustments in accumulated other comprehensive income (loss).

## Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements (unaudited), estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration and contingent value rights in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.

## Business Combination and Goodwill

The Company accounted for its acquisition of Alimera using the acquisition method of accounting prescribed by ASC 805, *Business Combinations*, whereby the results of operations, including the revenues and earnings of Alimera, are included in the financial statements from the date of acquisition. Assets acquired and liabilities assumed as of the date of acquisition are recognized at their fair values based on widely accepted valuation techniques in accordance with ASC 820, *Fair Value Measurements*. Goodwill is recognized for the excess of the consideration transferred over the net fair values of assets acquired and liabilities assumed. Management’s assessment of qualitative factors affecting goodwill for each acquisition includes estimates of market share at the date of purchase, ability to grow in the market, synergy with existing Company operations and the payor profile in the markets. The fair value assigned to the intangible assets was determined using the income approach, specifically the multi-period excess earnings methodology. The process for estimating fair values requires the use of significant estimates, assumptions and judgments, including determining the timing and estimates of future cash flows and developing appropriate discount rates. The estimates of fair value are based upon assumptions believed to be reasonable using the best information available. These assumptions are inherently uncertain and unpredictable and, as a result, actual results may differ materially from estimates.

ASC 805, *Business Combinations*, establishes a measurement period to provide the Company with a reasonable amount of time to obtain the information necessary to identify and measure various items in a business combination and cannot extend beyond one year from the acquisition date. Measurement period adjustments are recognized in the reporting period in which the adjustments are determined and calculated as if the accounting had been completed as of acquisition date. The Company has completed the final fair value determination of the assets acquired and liabilities assumed from Alimera, within the measurement period, which did not exceed one year from the acquisition date.

## Recent Accounting Pronouncements

### *Recently Issued Accounting Pronouncements Not Yet Adopted*

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

In November 2024, the FASB issued ASU 2024-03, *Disaggregation of Income Statement Expenses (DISE)*, which specifies additional disclosure requirements. The new guidance requires additional disclosures, including the composition of certain income expense line items (such as purchases of inventory, employee compensation, and "other expenses") and a separate disclosure for selling expenses. This change is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, however, early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on the consolidated financial statements and disclosures and anticipate adoption in the 2027 annual report on Form 10-K.

### *Recently Adopted Accounting Pronouncements*

In December 2023, the FASB issued Accounting Standards Update ("ASU") 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company has adopted the provisions of ASU 2023-09 as of January 1, 2025, and there is no impact on the unaudited interim condensed consolidated financial statements or notes to the financials.

## 2. REVENUE RECOGNITION AND RELATED ALLOWANCES

### Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, *Revenue from Contracts with Customers*. Revenue is recognized using the following steps:

- Identification of the contract, or contracts, with a customer;
- Identification of the performance obligations in the contract;
- Determination of the transaction price, including the identification and estimation of variable consideration;
- Allocation of the transaction price to the performance obligations in the contract; and
- Recognition of revenue when the Company satisfies a performance obligation.

Revenues are primarily derived from sales of generic, rare disease, and brands portfolio pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products is transferred to the customer. Variable consideration is estimated after the consideration of applicable information that is reasonably available. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because customers generally pay outstanding balances within 100 days.

All revenue recognized in the accompanying unaudited condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:

Products and Services (in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
<b>Rare Disease and Brands</b>				
Cortrophin Gel	\$ 101,850	\$ 52,555	\$ 236,347	\$ 138,685
ILUVIEN and YUTIQ	16,600	3,871	55,025	3,871
<b>Rare Disease total net revenues</b>	<b>\$ 118,450</b>	<b>\$ 56,426</b>	<b>\$ 291,372</b>	<b>\$ 142,556</b>
Brands	10,675	9,195	48,993	44,900
<b>Rare Disease and Brands total net revenues</b>	<b>\$ 129,125</b>	<b>\$ 65,621</b>	<b>\$ 340,365</b>	<b>\$ 187,456</b>
<b>Generics and Other</b>				
Generic pharmaceutical products	\$ 94,375	\$ 78,223	\$ 283,350	\$ 222,404
Royalties and other pharmaceutical services	4,313	4,488	12,591	13,942
<b>Generics and Other total net revenues</b>	<b>98,688</b>	<b>82,711</b>	<b>295,941</b>	<b>236,346</b>
<b>Total net revenues</b>	<b>\$ 227,813</b>	<b>\$ 148,332</b>	<b>\$ 636,306</b>	<b>\$ 423,802</b>

In the three and nine months ended September 30, 2025 and 2024, all of the Company's revenue was recognized at a point in time, when the performance obligation in the contracts with customers have been satisfied, generally when control of the products is transferred to the customer. The Company did not recognize any revenue associated with performance obligations satisfied over time.

In the three and nine months ended September 30, 2025 and 2024, the Company did not incur, and therefore did not defer, any material incremental costs to obtain or fulfill contracts. The Company recognized an additional \$1.3 million to net revenue from performance obligations satisfied in prior periods during the nine months ended September 30, 2025, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. The Company recognized a reduction of \$3.3 million to net revenue from performance obligations satisfied in prior periods during the nine months ended September 30, 2024, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales.

As of September 30, 2025, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open contract manufacturing customer contracts was \$2.1 million, which consists of firm orders for contract manufactured products. The Company recognizes revenue for these performance obligations as they are satisfied, which is anticipated within six months.

#### *Variable consideration*

Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment.

The following table summarizes activity in the unaudited condensed consolidated balance sheets for accruals and allowances for the nine months ended September 30, 2025 and 2024, respectively:

**Accruals for Chargebacks, Returns, and Other Allowances**

(in thousands)	Chargebacks	Government Rebates	Returns	Administrative Fees and Other Rebates	Prompt Payment Discounts
Balance at December 31, 2023	\$ 84,208	\$ 12,168	\$ 29,678	\$ 11,412	\$ 4,865
Impact of Alimera acquisition	95	—	3,095	671	—
Accruals/Adjustments	403,201	19,757	28,737	44,622	17,159
Credits Taken Against Reserve	(410,508)	(21,232)	(24,442)	(43,486)	(17,218)
Balance at September 30, 2024 (1)	<u>\$ 76,996</u>	<u>\$ 10,693</u>	<u>\$ 37,068</u>	<u>\$ 13,219</u>	<u>\$ 4,806</u>
Balance at December 31, 2024	\$ 105,630	\$ 18,714	\$ 39,274	\$ 19,588	\$ 6,258
Accruals/Adjustments	493,008	53,983	30,977	62,159	26,199
Credits Taken Against Reserve	(496,765)	(35,665)	(20,246)	(58,645)	(25,495)
Balance at September 30, 2025 (1)	<u>\$ 101,873</u>	<u>\$ 37,032</u>	<u>\$ 50,005</u>	<u>\$ 23,102</u>	<u>\$ 6,962</u>

(1) Chargebacks are included as an offset to accounts receivable, net of chargebacks and other allowances in the unaudited condensed consolidated balance sheets. Administrative Fees and Other Rebates and Prompt Payment Discounts are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the unaudited condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited condensed consolidated balance sheets. Government Rebates are included in accrued government rebates in the unaudited condensed consolidated balance sheets.

**Credit Concentration**

ANI's customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, pharmaceutical companies, hospitals, and healthcare providers.

During the three and nine months ended September 30, 2025, there were three customers that accounted for 10% or more of net revenues. During the three and nine months ended September 30, 2024, there were four customers that accounted for 10% or more of net revenues. As of September 30, 2025, accounts receivable from four customers totaled 72% of accounts receivable, net.

The four customers represent the total percentage of net revenues as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
<b>Customer 1</b>	13 %	20 %	19 %	26 %
<b>Customer 2</b>	7 %	10 %	9 %	12 %
<b>Customer 3</b>	17 %	14 %	14 %	12 %
<b>Customer 4</b>	26 %	17 %	21 %	15 %

**3. BUSINESS COMBINATION**

On September 16, 2024, the Company completed the previously announced acquisition (the "Acquisition" or the "Merger") of Alimera Sciences, Inc., a Delaware corporation ("Alimera") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Company, Alimera and ANIP Merger Sub INC., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub merged with and into Alimera, with Alimera surviving the Merger as a wholly owned subsidiary of the Company.

At the effective time of the Merger, each share of common stock, par value \$0.01 per share, of Alimera (the “Alimera Common Stock”) outstanding, including each Alimera RSA (as defined below), but excluding any treasury shares or shares owned by the Company, Merger Subs or any other subsidiary of the Company or Alimera, was canceled and ceased to exist and was converted into the right to receive (i) \$5.50 in cash (“Closing Cash Consideration”), and (ii) one contingent value right (a “CVR”), which represents the right to receive milestone payments subject to the terms and conditions set forth and as further described in the CVR Agreement entered into on September 16, 2024 (collectively, the “Merger Consideration”).

In addition to the amounts payable to the holders thereof in connection with the Closing, all of the outstanding awards of restricted stock with respect to shares of Alimera Common Stock (each, an “Alimera RSA”), each Alimera Performance Stock Unit (“Alimera PSU”), each Alimera Restricted Stock Unit (“Alimera RSU”) and each Alimera Warrant that were outstanding immediately prior to the Effective Time were automatically canceled and converted into the right to receive one (1) CVR per share of Alimera Common Stock then underlying the applicable instrument.

Each stock option previously granted by Alimera to purchase Alimera Common Stock (each, an “Alimera Option”) that was outstanding and unexercised as of the Effective Time and which had a per share exercise price that was less than the Closing Cash Consideration was, in addition to the amounts payable to the holders thereof in connection with the Closing, automatically canceled and converted into the right to receive one (1) CVR per share of Alimera Common Stock then underlying such Alimera Option. No other Alimera Options were cancelled and converted into the right to receive a CVR, provided that each Alimera Option with a per share exercise price greater than or equal to the Closing Cash Consideration but less than the Total Consideration (as defined in the Merger Agreement) may receive a payment in connection with the payout of the CVRs (if any).

This acquisition was accounted for as a business combination. Purchase consideration consisted of the following:

<b>(In thousands, except share price and exchange ratio)</b>	<b>Purchase Consideration</b>
Alimera common shares outstanding	53,971
Alimera warrants outstanding after exercise	989
Alimera common shares and warrants outstanding	54,960
Cash consideration per share	\$ 5.50
Cash consideration for Alimera Common Stock	\$ 302,280
Repayment of Alimera Debt	78,540
Payment of Alimera transaction costs	20,172
Cash settlement for pre-acquisition equity awards	9,535
Fair value of CVRs	8,322
<b>Total Merger Consideration</b>	<b>\$ 418,849</b>

The cash payment was funded through the New Credit Facility, see Note 6 “New Credit Agreement” to the notes to the condensed consolidated financial statements (unaudited) for further details, and also cash on hand from the Company’s balance sheet.

As part of the purchase consideration the Company paid approximately \$78.5 million for the repayment of the outstanding term loan Alimera had with SLR Investment Corp., including interest payable, prepayment and end of term fees. Furthermore, the Company repaid \$20.2 million of transaction costs incurred by Alimera.

In accordance with the terms of the Merger Agreement, the Company settled all outstanding equity awards held by Alimera employees, for a total cash amount of \$19.3 million, of which, \$1.3 million was paid in cash at the close of the Merger. Of the \$19.3 million, \$9.5 million was determined to be related to the pre-Merger services provided and as a result was allocated to the purchase consideration transferred. The remaining amounts were attributed to the post-Merger period and deemed to be for the benefit of ANI the Company. As a result, \$8.8 million was recognized as selling, general, and administrative and \$1.0 million as research and development expense, respectively, for the year ended December 31, 2024.

The CVRs represent a form of contingent consideration and are included as part of the purchase consideration transferred. The CVRs represent the right to future cash payments for the former Alimera shareholders based on certain 2026 and 2027 revenue targets. Management determined the contingent consideration to be liability classified and will measure the liability at fair value each reporting period. The fair value of the CVRs have been estimated using a Monte Carlo simulation under an option pricing framework, \$8.3 million of the total \$8.7 million was related to the pre-combination period and recognized as consideration transferred. The remaining \$0.4 million of the fair value of the CVR was allocated to post-merger period and recognized as selling, general, and administrative for the year ended December 31, 2024. The CVRs have been remeasured to fair value as of September 30, 2025, see Note 16 “Fair Value” in the notes to the condensed consolidated financial statements (unaudited).

The preliminary purchase price allocation, measurement period adjustments, and final purchase price allocation of the fair value of the Alimera acquisition is shown in the table below.

(in thousands)	Preliminary Purchase Price Allocation	Measurement Period Adjustment	Final Purchase Price Allocation
Cash and cash equivalents	\$ 9,247	\$ —	\$ 9,247
Accounts receivable	38,605	175	38,780
Prepaid expenses and other assets	2,618	—	2,618
Inventories	19,457	(1,559)	17,898
Property and equipment	3,086	—	3,086
Intangible assets	400,000	—	400,000
Deferred tax asset, net of deferred tax liabilities and valuation allowance	198	(84)	114
Derivative and other non-current assets	1,224	—	1,224
<b>Total assets</b>	<b>\$ 474,435</b>	<b>\$ (1,468)</b>	<b>\$ 472,967</b>
Accounts payable	\$ 8,001	\$ —	\$ 8,001
Accrued expenses and other	11,396	976	12,372
Accrued government rebates	—	385	385
Returned goods reserve	3,095	(2,600)	495
Current accrued licensor payment	3,684	—	3,684
Accrued licensor payment, net of current	21,316	—	21,316
Deferred tax liability	37,932	1,828	39,760
Other non-current liabilities	2,364	—	2,364
<b>Total liabilities</b>	<b>\$ 87,788</b>	<b>\$ 589</b>	<b>\$ 88,377</b>
<b>Total fair value of consideration transferred</b>	<b>\$ 418,849</b>	<b>\$ —</b>	<b>\$ 418,849</b>
Less: fair value of net acquired identifiable assets and liabilities	386,647	(2,057)	384,590
<b>Goodwill</b>	<b>\$ 32,202</b>	<b>\$ 2,057</b>	<b>\$ 34,259</b>

The net assets were recorded at their estimated fair value. In valuing acquired assets and liabilities, fair value estimates were based primarily on future expected cash flows, market rate assumptions for contractual obligations, and appropriate discount rates.

Subsequent to the acquisition date, the Company has updated certain amounts above based upon information that was not known to the Company as of the acquisition date. The Company determined that the adjustments are considered measurement period adjustments under the accounting guidance. The Company recorded a net increase to goodwill of approximately \$2.1 million, as a result of the adjustments based on matters existed at acquisition date but not known to the Company at that time, measurement period adjustments were recorded, from the acquisition date through the end of the measurement period. The purchase price allocation was finalized during the quarter ended September 30, 2025.

The fair value of finished goods inventory utilizes a sales comparison approach which estimates the selling price of the inventory in completed condition less costs of disposal and a reasonable profit allowance for the selling effort.

As part of the Merger, the Company acquired the product rights to ILUVIEN and YUTIQ. The fair value of the acquired intangible assets was determined using an income approach, and more specifically, the multi-period excess earnings methodology. The identifiable intangible assets acquired are amortized on a straight-line basis over their estimated useful lives. The following table summarizes the estimated fair value of identifiable intangible assets acquired and their remaining amortization period (in years):

(in thousands)	Fair Value	Amortization Period
ILUVIEN	\$ 230,000	12
YUTIQ	\$ 170,000	12

During the second quarter of 2025, the Company transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN with its combined label of DME and NIU-PS, and as a result the Company combined the ILUVIEN and YUTIQ intangible assets. The Company concluded that there were no changes to expected future cash flows for the combined ILUVIEN definite-lived intangible asset. The fair value of the definite-lived intangible asset was not below its carrying value as of September 30, 2025.

The estimated deferred tax liability, recognized based on the estimated tax impact of the differences between the financial reporting and tax bases of the assets and liabilities acquired, is included in Deferred tax assets, net of deferred tax liabilities and valuation allowance in the unaudited condensed consolidated balance sheet as of September 30, 2025.

Goodwill is calculated as the difference between the fair value of the final aggregate purchase consideration and the values assigned to the identifiable tangible and intangible assets acquired and liabilities assumed. Goodwill represents the workforce acquired, as well as future operating efficiencies and cost savings. The actual amount of goodwill will depend upon the final determination of the fair value of the assets acquired and liabilities assumed and may differ materially from this preliminary determination. Goodwill established as a result of the acquisition is tax deductible in the U.S.

#### ***Transaction Costs***

In conjunction with the acquisition, the Company incurred approximately \$0.4 million and \$1.6 million of transaction and integration costs during the three and nine months ended September 30, 2025, respectively, all of which were recognized as selling, general, and administrative expense in the unaudited condensed consolidated statement of operations. The Company incurred approximately \$9.8 million and \$13.2 million of transaction and integration costs during the three and nine months ended September 30, 2024, respectively.

#### **4. RESTRUCTURING CANADA OPERATIONS**

On March 31, 2023, the Company ceased operations at the Oakville, Ontario, Canada manufacturing plant. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium in November 2021. ANI has fully completed the transition of the products manufactured or packaged in Oakville to one of the Company's three U.S. based manufacturing sites.

There were no restructuring expenses recorded in the three and nine months ended September 30, 2025 and September 30, 2024, respectively, in the unaudited condensed consolidated statements of operations. As of September 30, 2025 and December 31, 2024, there was no severance or other employee benefits accrued on the unaudited condensed consolidated balance sheets.

On February 15, 2024, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement with 1540700 Ontario Limited for the sale of the property for a total purchase price of \$19.2 million Canadian Dollars, or approximately \$14.2 million, based on the exchange rate at closing. On March 28, 2024 the Company completed the sale of the property. After payment of commissions, real estate taxes, and other related costs of approximately \$0.7 million, the Company received a net proceeds of approximately \$13.5 million at closing. The gain on the sale of the property was approximately \$5.3 million, recorded in the unaudited condensed consolidated statements of operations for the nine months ended September 30, 2024.

#### **5. TRUIST CREDIT FACILITY**

In connection with the acquisition of Novitium on November 19, 2021, the Company, as borrower, entered into a credit agreement (the "Credit Agreement") with Truist Bank and other lenders, which provided for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of \$300.0 million (the "Term Facility") and (ii) a senior secured revolving credit facility in an aggregate commitment amount of \$40.0 million, which provided for revolving credit loans, swingline loans and letters of credit (the "Revolving Facility," and together with the Term Facility, the "Credit Facility").

The Company incurred \$14.0 million in deferred debt issuance costs associated with the Credit Facility. Costs allocated to the Term Facility were classified as a direct reduction to the current and non-current portion of the borrowings, depending on their nature. Costs allocated to the Revolving Facility were classified as other current and other non-current assets, depending on their nature. A commitment fee of 0.5% per annum was assessed on any unused portion of the Revolving Facility.

### ***Extinguishment of the Credit Facility***

On August 13, 2024, the Company entered into an indenture with U.S. Bank Trust Company, National Association, as trustee, for the issuance of the 2.25% Convertible Senior Notes due 2029 (the "Notes") (as described in Note 7 "2.25% Convertible Senior Notes" to the notes to the condensed consolidated financial statements (unaudited)). The proceeds of the Notes and cash on-hand were used to repay the Credit Facility in its entirety, approximately \$294.0 million, comprised of \$292.5 million of unpaid principal, \$1.2 million in accrued and unpaid interest, and \$0.3 million of legal fees. In connection with the issuance of the Notes, the Company recorded a loss on debt extinguishment in the unaudited consolidated statement of operations for the year ended December 31, 2024, amounting to approximately \$7.5 million, comprised of the write-off unamortized deferred financing fees related to the Credit Facility as of August 13, 2024. As of September 30, 2025 and December 31, 2024 there were no amounts outstanding related to the Credit Facility reported in the unaudited condensed consolidated balance sheets.

The following table sets forth the total interest expense related to the Credit Facility, as recognized in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024:

<b>(in thousands)</b>	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2024</b>		<b>2024</b>	
Contractual coupon	\$	2,883	\$	16,644
Amortization of deferred financing costs		295		1,477
Capitalized interest		(138)		(401)
	\$	3,040	\$	17,720

## **6. NEW CREDIT AGREEMENT**

On August 13, 2024, the Company, as lead borrower, and ANIP Acquisition Company, as initial subsidiary borrower ("ANIP") entered into a credit agreement (the "New Credit Agreement") with JPMorgan Chase Bank, N.A., as administrative agent, and the financial institutions party thereto as lenders, which provides for aggregate principal commitments consisting of (i) a senior secured delayed-draw term loan facility in an aggregate principal amount of \$325.0 million (the "Term Loan A" or "TLA"), and (ii) a senior secured revolving credit facility in an aggregate commitment amount of \$75.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the "TLA Revolver" and together with the TLA, the "New Credit Facility").

On September 16, 2024 (the "Closing Date"), ANIP drew the full \$325.0 million of Term Loan A principal, with proceeds used to finance the acquisition of Alimera, including fees, costs and expenses incurred in connection with the acquisition. As of September 30, 2025, \$74.9 million is available for borrowing under the TLA Revolver. The TLA and the TLA Revolver mature on September 16, 2029. The New Credit Facility contains certain contingent acceleration clauses that could result in an earlier maturity date, none of which have been triggered as of September 30, 2025.

The cash interest rate and effective rate under the Term Loan A was approximately 6.76% and 7.12% per annum at September 30, 2025, respectively.

The New Credit Facility is secured by a lien on substantially all of the Company's and its principal domestic subsidiary's assets and any future domestic subsidiary guarantors' assets. The New Credit Facility is subject to customary financial and nonfinancial covenants. As of September 30, 2025, the Company was in compliance with all covenants associated with the New Credit Facility.

The Company is required to make quarterly principal payments, beginning on December 31, 2024, in the amount of (i) 0.625% of the original principal amount of the Term Loan A on each quarterly payment date on or prior to the one year anniversary of the Closing Date, (ii) 1.25% of the original principal amount of the Term Loan A on each quarterly payment date following the one year anniversary of the Closing Date and 1.875% of the original principal amount of the Term Loan A on each quarterly payment date following the three year anniversary of the Closing Date and with the remaining unpaid principal amount due on the maturity date of the Term Loan A. A commitment fee accrues on the unutilized commitments under the TLA Revolver and, from and after the date that is two months after the closing date of the New Credit Agreement, the TLA at a per annum rate equal between 0.25% and 0.40% depending on the Company's first lien net leverage ratio.

The Company incurred \$5.0 million in deferred debt issuance costs associated with the TLA, which costs are classified as a direct reduction to the current and non-current portion of debt. The Company incurred \$1.1 million in deferred debt issuance costs associated with the TLA Revolver. Of the approximately \$0.9 million of unamortized deferred debt issuance costs allocated to the

TLA Revolver, \$0.7 million is included in other non-current assets in the unaudited condensed consolidated balance sheets, and \$0.2 million is included in prepaid expenses and other current assets in the unaudited condensed consolidated balance sheets.

The carrying value of the current and non-current components of the New Credit Facility as of September 30, 2025 and December 31, 2024 are:

(in thousands)	Current	
	September 30, 2025	December 31, 2024
Current borrowing on debt	\$ 16,250	\$ 10,156
Deferred financing costs	(1,009)	(984)
Current debt, net of deferred financing costs	\$ 15,241	\$ 9,172

(in thousands)	Non-Current	
	September 30, 2025	December 31, 2024
Non-current borrowing on debt	\$ 300,625	\$ 312,813
Deferred financing costs	(2,948)	(3,705)
Non-current debt, net of deferred financing costs and current component	\$ 297,677	\$ 309,108

The contractual maturity of the Term Loan A is as follows for the period ending:

(in thousands)	New Credit Facility	
2025 (remainder of the year)	\$	4,062
2026		18,281
2027		24,375
2028		24,375
2029		245,782
Total	\$	316,875

The following table sets forth the components of total interest expense, net recognized in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2025 and 2024:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Contractual coupon interest expense, Truist	\$ —	\$ (4,003)	\$ —	\$ (20,993)
Contractual coupon interest expense, Term Loan A	\$ (5,662)	(1,061)	(16,806)	(1,061)
Contractual coupon interest expense, Convertible Notes	\$ (1,779)	(969)	(5,317)	(969)
Amortization of deferred financing costs	\$ (838)	(625)	(2,484)	(1,806)
Interest expense	(8,279)	(6,658)	(24,607)	(24,829)
Capitalized interest related to Construction in Progress	115	138	269	401
Interest and dividend income on bank balances	2,180	2,537	4,957	7,960
Interest income on interest rate swap	1,257	1,652	3,732	4,881
Interest income	3,552	4,327	8,958	13,242
Interest expense, net	\$ (4,727)	\$ (2,331)	\$ (15,649)	\$ (11,587)

## 7. 2.25% CONVERTIBLE SENIOR NOTES

### *Offering of Convertible Senior Notes*

On August 7, 2024, the Company entered into a purchase agreement (the “Purchase Agreement”) with the initial purchasers (the “Initial Purchasers”) relating to the issuance of the \$275.0 million aggregate principal amount of the Company's Convertible Senior Notes due 2029 (the “Notes”). Pursuant to the terms of the Purchase Agreement, the Company granted the Initial Purchasers an option to purchase up to an additional \$41.3 million aggregate principal amount of Notes (the “Option”) for settlement at any time during the thirteen days beginning on, and including August 7, 2024, which Option was exercised in full on August 8, 2024.

On August 13, 2024, the Company completed an offering of \$316.3 million aggregate principal amount of Notes. The Notes were issued pursuant to an indenture (the “Indenture”) dated as of August 13, 2024 between the Company and U.S. Bank Trust Company, National Association. The Notes are due September 1, 2029, unless earlier repurchased, redeemed, or converted. The Notes will accrue interest at a rate of 2.25% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2025. After deducting the initial purchasers' discounts and commissions of approximately \$9.5 million, but before deducting the Company's offering expenses, the net proceeds to the Company from the offering of the Notes was approximately \$306.8 million.

After payment of the cost of entering into the Capped Call Transactions (as defined below), the Company used the remainder of the net proceeds from the Notes offering, together with cash on hand, to repay the Company's existing senior secured credit agreement, dated as of November 19, 2021, by and among the Company, certain of the Company's subsidiaries, as guarantors, Truist Bank, as administrative agent, and other parties thereto, as amended, supplemented or otherwise modified from time to time. Refer to Note 5 “Truist Credit Facility” to the notes to the condensed consolidated financial statements (unaudited) for the details of the extinguishment of the Credit Agreement.

The Notes are the Company's senior, unsecured obligations and are (i) equal in right of payment with the Company's existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company's existing and future indebtedness that is expressly subordinated to the Notes; (iii) effectively subordinated to the Company's existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company's subsidiaries.

Debt issuance costs related to the Notes totaled \$11.2 million at inception and were comprised of discounts and commissions payable to the initial purchasers and third-party offering costs and will be amortized to interest expense using the effective interest method over the contractual term. As of September 30, 2025 and December 31, 2024, the unamortized debt issuance costs of the Notes was approximately \$8.9 million and \$10.4 million, respectively. The effective interest rate during the quarter ended September 30, 2025 was 3.01%.

The Company recognized \$1.8 million and \$5.3 million of contractual coupon interest expense and \$0.5 million and \$1.6 million of interest expense related to the amortization of deferred financing costs for the three and nine months ended September 30, 2025, respectively.

The Company recognized \$1.0 million of contractual coupon interest expense and \$0.3 million of interest expense related to the amortization of deferred financing costs for the three and nine months ended September 30, 2024, respectively.

As of September 30, 2025, the total estimated fair value (which represents a Level 2 valuation) of the Notes is approximately \$444.6 million.

### *Conversion Options*

Prior to the close of business on the business day immediately preceding June 1, 2029, holders of the Notes will have the right to convert their Notes only upon the occurrence of certain events as set forth in the Indenture. All or any portion of the Notes may be converted prior to June 1, 2029 at the holders' option upon the occurrence of any of the following: (i) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on September 30, 2024, if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price of the Notes for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (ii) during the five consecutive business days immediately after any ten consecutive trading day period (such ten consecutive trading day period, the “measurement period”) in which the trading price per \$1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company's common stock on such trading day and the conversion rate of the Notes on such trading day; (iii) upon the occurrence of certain corporate events or distributions on the Company's common stock, as described in the Indenture; or (iv) if the Company calls such Notes for redemption.

On or after June 1, 2029 until the close of business on the second scheduled trading day immediately before the maturity date of the Notes, holders may convert all or any portion of their Notes at any time at their election. The initial conversion rate for the Notes is 13.4929 shares of the Company's common stock per \$1,000 principal amount of Notes, which represents an initial conversion price of approximately \$74.11 per share of the Company's common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a "Make-Whole Fundamental Change" (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for holders that convert their Notes in connection with such Make-Whole Fundamental Change, as described in the Indenture.

Upon conversion of the Notes, the Company will pay cash up to the aggregate principal amount of the Notes to be converted and pay or deliver, as the case may be, cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's election, in respect of the remainder, if any, of the Company's conversion obligation.

The Notes will be redeemable, in whole or in part (subject to certain limitations described below), at the Company's option at any time, and from time to time, on or after September 1, 2027 and on or before the 61st scheduled trading day immediately before the maturity date, but only if (i) the notes are "Freely Tradable" (as defined in the Indenture) as of the date the Company sends the related redemption notice and all accrued and unpaid additional interest, if any, has been paid in full as of the first interest payment date occurring on or before the date the Company sends the related redemption notice; and (ii) the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends such redemption notice; and (2) the trading day immediately before the date the Company sends such redemption notice.

However, the Company may not redeem less than all of the outstanding Notes unless at least \$75.0 million aggregate principal amount of Notes are outstanding and not called for redemption as of the time the Company sends the related redemption notice. The redemption price will be a cash amount equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted with a conversion date that is on or after the date the Company sends the related redemption notice and on or before the second business day immediately before the related redemption date.

If certain corporate events that constitute a "Fundamental Change" (as defined in the Indenture) occur, then, subject to a limited exception for certain cash mergers, holders of the Notes may require the Company to repurchase their Notes at a cash repurchase price equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company's common stock.

#### ***Events of Default***

The Notes include customary provisions relating to the occurrence of "Events of Default" (as defined in the Indenture), including breaches of covenants, breaches of warranty, change of control, nonpayment, bankruptcy, assignment, foreclosure, cessation of business, and defaults under ancillary documents. Certain of the Events of Default are subject to notice and cure periods. As of September 30, 2025, the Company was in compliance with all covenants associated with the Notes.

During the quarter ended September 30, 2025, the Notes did not meet any of the circumstances that would allow for a conversion. The Notes were therefore not convertible as of September 30, 2025, and were classified as long-term debt on the Company's unaudited condensed consolidated balance sheet as of September 30, 2025.

#### ***Capped Call Transactions***

In connection with the offering of Notes, on August 7, 2024 and August 8, 2024, the Company entered into capped call transactions with certain financial institutions ("Capped Calls"). The Capped Calls each have an initial cap price of \$114.02, which represents a premium of 100% over the last reported sale price of the Company's common stock on August 7, 2024. The Company used approximately \$40.6 million of the net proceeds from the offering of the Notes to pay premiums on the Capped Calls. The Capped Calls cover, subject to anti-dilution adjustments, approximately 4.3 million shares of the Company's common stock.

## 8. DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY

In April 2020, the Company entered into an interest rate swap with Citizens Bank, N.A. to manage its exposure to changes in the London Interbank Offered Rate (“LIBOR”) LIBOR-based interest rates underlying total borrowings under term facilities related to the prior credit agreement, and the interest rate swap matures in December 2026. The Company amended its Credit Agreement to transition from LIBOR to the Secured Overnight Financing Rate (“SOFR”) due to the cessation of LIBOR in the third quarter of 2023, and accordingly, the interest rate swap transitioned from LIBOR to SOFR. The interest rate swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the Term Facility. Concurrent with the termination of the prior credit agreement and entry into the Credit Agreement with Truist Bank, the interest rate swap with a notional value of \$168.6 million at origin on November 21, 2021 was novated and Truist Bank became the new counterparty.

On August 30, 2024, in connection with the New Credit Facility, the interest rate swap with a notional value of \$139.4 million was transferred from Truist Bank to JPMorgan Chase Bank, N.A., as the new counterparty. The interest rate swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the New Term Facility. The interest rate swap provides an effective fixed interest rate of 2.313% and is designated as an effective cash flow hedge and therefore qualifies for hedge accounting. As of September 30, 2025, the notional amount of the interest rate swap was \$139.4 million, and will remain static until maturity in December 2026. As of September 30, 2025, the fair value of the interest rate swap asset recorded in other non-current assets in the unaudited condensed consolidated balance sheets is \$2.2 million. As of September 30, 2025, \$2.6 million was recorded in accumulated other comprehensive income (loss), net of tax in the unaudited condensed consolidated balance sheets.

During the three and nine months ended September 30, 2025, the loss on the fair value of the interest rate swaps, net of tax recorded in accumulated other comprehensive income (loss) in the unaudited condensed consolidated statements of comprehensive income (loss) was approximately \$0.9 million and \$3.5 million, respectively. Differences between the hedged SOFR rate and the fixed rate are recorded as interest expense in the same period that the related interest is recorded for the Term Facility based on the SOFR rate. In the three and nine months ended September 30, 2025, the Company recorded a reduction in interest expense of \$1.3 million and \$3.7 million in relation to the interest rate swaps, respectively. In the three and nine months ended September 30, 2024, the Company recorded a reduction in interest expense of \$1.7 million and \$4.9 million in relation to the interest rate swaps, respectively. Included in this amount for the three and nine months ended September 30, 2025 are reclassifications of interest income out of accumulated other comprehensive income (loss) of \$0.9 million and \$2.7 million, respectively, related to terminated and de-designated cash flow hedges. Included in this amount for the three and nine months ended September 30, 2024 are reclassifications of interest income out of accumulated other comprehensive (loss) income of \$0.2 million and \$0.6 million, respectively, related to terminated and de-designated cash flow hedges.

## 9. EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share is computed by dividing net income available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting of shares issuable upon conversion of the Company's senior convertible notes, common stock options, shares to be purchased under the 2016 Employee Stock Purchase Plan (“ESPP”), and performance stock units, using the more dilutive of the treasury stock or the two-class method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share.

Unvested restricted share awards, unvested restricted units, Series A convertible preferred stock shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic and diluted earnings (loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and the common shares assumed converted from the preferred shares and excludes the impact of those shares from the denominator. The Company's participating securities do not have a contractual obligation to share in the Company's losses. As such, the net loss was attributed entirely to common stockholders.

Earnings (loss) per share for the three and nine months ended September 30, 2025 and 2024 are calculated for basic and diluted earnings per share as follows:

(in thousands, except per share amounts)	Basic		Diluted		Basic		Diluted	
	Three Months Ended September 30,		Three Months Ended September 30,		Nine Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024	2025	2024	2025	2024
Net income (loss) available to common shareholders	\$ 26,273	\$ (24,572)	\$ 26,273	\$ (24,572)	\$ 49,690	\$ (9,465)	\$ 49,690	\$ (9,465)
Earnings allocated to participating securities	(2,483)	—	(2,374)	—	(4,860)	—	(4,634)	—
Net income (loss) available to common shareholders	\$ 23,790	\$ (24,572)	\$ 23,899	\$ (24,572)	\$ 44,830	\$ (9,465)	\$ 45,056	\$ (9,465)
Basic Weighted-Average Shares Outstanding	20,074	19,404	20,074	19,404	19,840	19,275	19,840	19,275
Dilutive effect of convertible senior notes, performance stock units, common stock options, and ESPP			1,019	—			1,071	—
Diluted Weighted-Average Shares Outstanding			21,093	19,404			20,911	19,275
Earnings (loss) per share	\$ 1.19	\$ (1.27)	\$ 1.13	\$ (1.27)	\$ 2.26	\$ (0.49)	\$ 2.15	\$ (0.49)

The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings per share were 1.6 million and 2.1 million for the three and nine months ended September 30, 2025, respectively, because including them would have been anti-dilutive.

The number of shares of potentially dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders was 2.7 million and 2.3 million for the three and nine months ended September 30, 2024, respectively, because including them would have been anti-dilutive. The Company has also excluded approximately 4.3 million shares from the computation of diluted net loss per share for the three and nine months ended September 30, 2024, representing the maximum number of conversion shares from the 2.25% Convertible Senior Notes.

## 10. INVENTORIES

Inventories consist of the following as of:

(in thousands)	September 30, 2025	December 31, 2024
Raw materials	\$ 68,649	\$ 67,174
Packaging materials	9,711	9,977
Work-in-progress	5,000	1,665
Finished goods	63,115	57,966
Inventories	\$ 146,475	\$ 136,782

### Vendor Concentration

Raw materials are sourced for products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the cost and time required to validate a second source of supply. As a result, the Company is dependent upon our current vendors to reliably supply the API required for on-going product manufacturing. During the three and nine months ended September 30, 2025, approximately 21% and 22%, respectively, of our raw material inventory purchases were from one domestic supplier. During the three months ended September 30, 2024, no single vendor represented more than 10% of our raw inventory purchases. During the nine months ended September 30, 2024, approximately 17% of our raw material inventory purchases were from one domestic supplier.

## 11. GOODWILL AND INTANGIBLE ASSETS

### Goodwill

As of September 30, 2025, the Company has assigned its goodwill in three reporting units, Generics and Other, Brands, and Rare Disease reporting units. As a result of the 2013 merger with BioSante Pharmaceuticals, Inc., the Company recorded goodwill of \$1.8 million. As a result of the acquisition of WellSpring Pharma Services Inc. in 2018, the Company recorded goodwill of \$1.7 million. From the acquisition of Novitium in 2021, the Company recorded goodwill of \$24.6 million. The goodwill from the transactions with BioSante Pharmaceuticals, Inc., WellSpring Pharma Services Inc., and Novitium is recorded in the Generics and Other reporting unit. As a result of the acquisition of Alimera, on September 16, 2024, the Company recorded goodwill of approximately \$34.3 million in the Rare Disease reporting unit. Refer to Note 3 “Business Combination” to the notes to the condensed consolidated financial statements (unaudited) for further information related to the acquisition. There have been no events or changes in circumstances that would have reduced the fair value of the reporting units below their carrying value during the three and nine months ended September 30, 2025, and 2024, respectively, and as a result no impairment charges have been recognized.

### Intangible Assets

The components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows:

(in thousands)	September 30, 2025			December 31, 2024			Remaining Weighted Average Amortization Period(1)
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	
<b>Definite-Lived Intangible Assets:</b>							
Acquired ANDAs intangible assets	\$ 214,174	\$ (142,198)	\$ 71,976	\$ 210,497	\$ (124,874)	\$ 85,623	3.9 years
NDA and product rights	673,554	(257,883)	415,671	641,271	(216,420)	424,851	10.5 years
Marketing and distribution rights	17,157	(15,955)	1,202	17,157	(15,233)	1,924	1.2 years
Customer relationships	24,900	(13,932)	10,968	24,900	(11,264)	13,636	3.1 years
Total Definite-Lived Intangible Assets	929,785	(429,968)	499,817	893,825	(367,791)	526,034	9.4 years
<b>Indefinite-Lived Intangible Assets:</b>							
In process research and development	—	—	—	15,800	—	15,800	Indefinite
Total Intangible Assets, net	\$ 929,785	\$ (429,968)	\$ 499,817	\$ 909,625	\$ (367,791)	\$ 541,834	

(1) Weighted average amortization period as of September 30, 2025.

Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (“ANDAs”), New Drug Applications (“NDAs”) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that these assets might be impaired.

During the year ended December 31, 2024, the Company acquired Alimera, and as a result, acquired two intangible assets for YUTIQ and ILUVIEN, in the amount of \$170.0 million and \$230.0 million, respectively, which are being amortized over a period of twelve years.

Pursuant to a Royalty Purchase Agreement dated as of December 17, 2020, EyePoint Pharmaceuticals US, Inc. (f/k/a pSivida US, Inc. or “EyePoint”) sold its right to receive royalty payments on future sales of ILUVIEN to SWK Funding LLC (“SWK”) under an existing collaboration agreement entered into in July 2017 between EyePoint and the Company (the “RPA Transaction”). In connection with the RPA Transaction, the Company agreed to pay such royalty payments directly to SWK. On June 19, 2024, Alimera entered into a letter agreement with SWK, pursuant to which the parties agreed to a lower fixed royalty payment of 3.125% (the “Alternative Royalty”) on combined sales of ILUVIEN and YUTIQ. The letter agreement included a buy-out of the Alternative Royalty at Alimera’s option at any time during the period within six (6) months after a change of control of Alimera, after which SWK would have no further right to receive any payments under the letter agreement or the RPA (the “Buy-Out Option”). On March 17, 2025, the Company exercised the Buy-Out Option and paid SWK \$17.3 million with cash on hand, and as such, no further royalty is due to SWK on net revenues beginning January 1, 2025, forward. The purchase of the Buy-Out Option was recorded as a definite-lived intangible asset, which will be amortized over a period of approximately twelve years, consistent with the useful lives of YUTIQ and ILUVIEN. The SWK definite-lived intangible asset is included in the “NDAs and product rights” in the table above.

Additionally, during the three months ended September 30, 2025, approximately \$0.7 million of acquired ANDA intangible assets were capitalized related to asset acquisitions during the period, which will be amortized over their useful lives.

Amortization expense for definite-lived intangibles was \$20.4 million and \$62.2 million million for the three and nine months ended September 30, 2025, respectively. Amortization expense for definite-lived intangibles was \$13.9 million and \$39.8 million for the three and nine months ended September 30, 2024, respectively.

Indefinite-lived intangible assets other than goodwill include primarily In-Process Research & Development (“IPR&D”) projects. IPR&D intangible assets represent the fair value of technology acquired in a business combination or asset acquisition for which the technology projects are incomplete but have substance or alternative future use. When an IPR&D project is completed (generally upon receipt of regulatory approval), then the IPR&D will be accounted for as a definite-lived intangible asset.

During the three months ended June 30, 2025, \$15.8 million was reclassified from indefinite-lived IPR&D to definite-lived NDAs and Product Rights related to the commercialization of Tezruly™ and Inzirqo™, and will be amortized over ten years. As of September 30, 2025 there was no IPR&D on the unaudited interim condensed consolidated balance sheet.

During the second quarter of 2025, the Company transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN with its combined label of DME and NIU-PS, and as result the Company combined the ILUVIEN and YUTIQ intangible assets. The Company concluded that there were no changes to expected future cash flows for the combined ILUVIEN definite-lived intangible asset.

The Company recognized approximately \$0.8 million of impairment charges during the three and nine months ended September 30, 2025, related to one product for which the Company has ceased commercialization. There were no impairment charges during the three and nine months ended September 30, 2024.

Expected future amortization expense for definite-lived intangible assets is as follows:

<b>(in thousands)</b>	
2025 (remainder of the year)	\$ 20,347
2026	69,620
2027	60,554
2028	54,563
2029	48,324
2030 and thereafter	246,409
<b>Total</b>	<b>\$ 499,817</b>

Expected amortization expense is an estimate. Actual amounts of amortization expense may differ due to additional intangible assets acquired, impairment of intangible assets, and other events.

## 12. MEZZANINE AND STOCKHOLDERS’ EQUITY

### Stockholders’ Equity

#### *Authorized shares*

At the 2025 Annual Meeting, the stockholders of the Company approved the amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 33.3 million shares to 66.0 million shares.

The Company is authorized to issue up to 66.0 million shares of common stock with a par value of \$0.0001 per share, 0.8 million shares of class C special stock with a par value of \$0.0001 per share, and 1.7 million shares of undesignated preferred stock with a par value of \$0.0001 per share at September 30, 2025.

There were 23.1 million and 22.5 million shares of common stock issued and outstanding as of September 30, 2025, respectively, and 21.5 million and 21.1 million shares of common stock issued and outstanding as of December 31, 2024, respectively.

### ***Class C Special Stock***

There were 11 thousand shares of class C special stock issued and outstanding as of September 30, 2025 and December 31, 2024. Each share of class C special stock entitles its holder to one vote per share. Each share of class C special stock is exchangeable, at the option of the holder, for one share of common stock, at an exchange price of \$90.00 per share, subject to adjustment upon certain capitalization events. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of our assets upon liquidation, dissolution, or winding-up the Company. The holders of class C special stock have no cumulative voting, preemptive, subscription, redemption, or sinking fund rights.

### **Mezzanine Equity**

#### ***PIPE Shares***

On March 8, 2021, concurrently with the acquisition of Novitium, and as financing for a portion of the acquisition, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the “PIPE Investor”), pursuant to which the PIPE Investor purchased 25,000 shares of Series A Convertible Preferred Stock (the “PIPE Shares”), for a purchase price of \$1,000 per share and an aggregate purchase price of \$25.0 million on November 19, 2021. The PIPE Shares were classified as mezzanine equity because the shares were mandatorily redeemable for cash upon a change in control, an event that was not solely within the Company’s control.

The PIPE Shares accrued dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and participated, on a pro-rata basis, in any dividends that would be declared with respect to the Company’s common stock. The PIPE Shares were convertible into common shares at the conversion price of \$41.4662 (i) beginning two years after their issuance date, at the election of ANI, if the volume-weighted average price of the common stock for any 20 trading days out of 30 consecutive trading days exceeds 170% of the conversion price, or (ii) at any time after issuance, at the election of the PIPE Investor.

On August 14, 2025, the PIPE Investor converted 5,000 PIPE Shares into 120,580 shares of common stock based on the conversion price of \$41.4662 per share. On September 26, 2025, the Company mandatorily converted the remaining 20,000 outstanding PIPE Shares into 482,320 shares of common stock based on the conversion price of \$41.4662 per share, as the conditions for conversion had been satisfied.

There were no shares of Series A convertible preferred stock outstanding as of September 30, 2025.

## **13. STOCK-BASED COMPENSATION**

### **Employee Stock Purchase Plan**

In July 2016, the Company commenced administration of the ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan, or ESPP. Under the ESPP, participants can purchase common shares of the Company’s stock at a 15% discount on the lowest share price on the first day of the purchase period or the last day of the purchase period.

During the 2025 Annual Meeting, the stockholders of the Company approved an amendment to the ESPP. Subject to adjustment, the Amended and Restated ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan, or Amended and Restated ESPP, authorized the issuance of an additional 500,000 shares.

As of September 30, 2025, the Company had approximately 0.5 million shares of common stock available under the Amended and Restated ESPP.

### **Stock Incentive Plan**

During the 2025 Annual Meeting, the stockholders of the Company approved an amendment to the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan, or 2022 Stock Plan (such amendment, the “2025 Stock Plan Amendment” and the 2022 Stock Plan, after giving effect to the 2025 Stock Plan Amendment, the Amended 2022 Stock Plan. Subject to adjustment, the 2025 Stock Plan Amendment authorizes the issuance of an additional 750,000 shares.

As of September 30, 2025, 1.9 million shares of common stock were available for issuance under the Amended 2022 Stock Plan.

### **Stock Options**

Outstanding stock options to purchase shares of common stock are granted to employees and consultants generally vest over a period of four years and have 10-year contractual terms. Outstanding stock options granted to non-employee directors generally vest over a period of one to four years and have 10-year contractual terms.

From time to time, stock options are granted to employees through an inducement grant outside of the Amended 2022 Stock Plan to induce prospective employees to accept employment with the Company (the “Inducement Grants”). The options are granted at an exercise price equal to the fair market value of a share of common stock on the respective grant date and are generally exercisable in four equal annual installments beginning on the first anniversary of the respective grant date. The grants are made pursuant to inducement grants outside of our stockholder approved equity plan as permitted under the Nasdaq Stock Market listing rules.

### **Restricted Stock Awards**

Restricted stock awards (“RSAs”) granted to employees generally vest over a period of four years and RSAs granted to non-officer directors generally vest over a period of one year. During the vesting period, the recipient of the RSAs has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the recipient prior to vesting. The fair value of each RSA is based on the market value of the Company's stock on the date of grant. Upon vesting, unrestricted shares of common stock are delivered to employees and directors.

### **Restricted Stock Units**

Restricted stock units (“RSUs”) are typically granted to international employees of the Company under the Amended 2022 Stock Plan, and generally vest over a period of four years. Each RSU will entitle the recipient to receive one unrestricted share of common stock upon vesting. The fair value of each RSU is based on the market value of the Company's stock on the date of grant.

### **Performance-Based Restricted Stock Units**

Awards may also be issued in the form of performance stock units (“PSUs”). PSUs represent the right to receive a number of shares of Company common stock, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted to date vest over a three-year performance period. The Company has granted PSUs on February 12, 2025, February 14, 2024, and February 28, 2023. Below is the description of the February 12, 2025 PSU grants.

#### ***February 12, 2025 Performance-Based Restricted Stock Units***

On February 12, 2025, as part of the Company's equity compensation program, PSUs were granted to certain executives. Of these PSUs, 50% were market performance-based restricted stock units (“MPRSUs”), vesting of which is contingent upon the Company meeting certain total shareholder return (“TSR”) levels as compared to a select peer group over the over three years starting January 1, 2025, and 50% of the PSUs were performance based restricted stock units (“PRSUs”), vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over three years starting January 1, 2025. The MPRSUs and PRSUs are also subject to the recipient's continued employment or service through December 31, 2027. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term.

On February 12, 2025, the Company granted 79,859 PSUs to employee and officers of the Company under the 2022 Plan (74,421 to officers of the Company). As described above, PSU performance will be measured over three-year performance period from January 1, 2025 through December 31, 2027 and will cliff-vest contingent upon the achievement of specified performance objectives. Both the MPRSUs and the PRSUs have a maximum potential to vest at 200%. At each reporting period, the Company analyzes progress on the performance goals to assess the likelihood of achievement.

The estimated grant date fair value per share of the MPRSUs was \$97.48 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the three-year performance period and are reflected under “Granted” in the table below.

The estimated grant date fair value per share of the PRSUs was \$59.68 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the three-year performance period and are reflected under “Granted” in the table below.

A summary of stock options (including Inducement Grants), RSA, RSU, and PSU activity under the Amended 2022 Stock Plan and Inducement Grants during the nine months ended September 30, 2025 and 2024 is presented below:

(in thousands)	Options	PSUs	RSAs	RSUs
Outstanding at December 31, 2023	689	84	1,351	—
Granted	—	74	669	—
Options Exercised/RSAs Vested	(57)	—	(467) <sup>(1)</sup>	—
Forfeited	(1)	—	(60)	—
Outstanding at September 30, 2024	631	158	1,493	—
Outstanding at December 31, 2024	584	150	1,455	—
Granted	—	80	710	22
Options Exercised/RSAs Vested	(196)	—	(528) <sup>(2)</sup>	—
Forfeited	(36)	—	(83)	—
Outstanding at September 30, 2025	352	230	1,554	22

<sup>(1)</sup> Includes 160 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the \$10.6 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited condensed consolidated balance sheets.

<sup>(2)</sup> Includes 184 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the \$11.6 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited condensed consolidated balance sheets.

The following table summarizes stock-based compensation expense incurred for ESPP incurred under the 2016 Employee Stock Purchase Plan, stock options, restricted stock awards, restricted stock units, performance-based restricted stock units, and Inducement grants included in the accompanying unaudited condensed consolidated statements of operations:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Cost of sales	\$ 516	\$ 318	\$ 1,296	\$ 911
Research and development	515	441	1,624	1,071
Selling, general, and administrative	8,660	6,725	25,241	20,301
Total	\$ 9,691	\$ 7,484	\$ 28,161	\$ 22,283

#### 14. INCOME TAXES

The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.

The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As of September 30, 2025, a valuation allowance was recorded against consolidated net deferred tax assets of \$9.5 million, related primarily to deferred tax assets for net operating loss carryforwards in certain U.S. state and foreign jurisdictions.

The Company uses a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company has not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements. The Company recognizes interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense; the Company did not have any such amounts accrued as of September 30, 2025 and December 31, 2024. The Company is subject to income tax audits in all jurisdictions for which tax returns are filed. Tax years from 2022 to 2024 remain subject to examination, with the exception of the assessment of NOL carry-forwards available for utilization, which can be examined for all years. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized.

For interim periods, the Company recognizes an income tax expense (benefit) based on our estimated annual effective tax rate, calculated on a worldwide consolidated basis, expected for the entire year. The interim annual estimated effective tax rate is based on the statutory tax rates then in effect, as adjusted for estimated changes in estimated permanent differences and excludes certain discrete items whose tax effect, when material, are recognized in the interim period in which they occur. These changes in permanent differences and discrete items result in variances to the effective tax rate from period to period. The Company's estimated annual effective tax rate changes throughout the year as our on-going estimates of pre-tax income, and changes in permanent differences are revised, and as discrete items occur. Global Intangible Low-Taxed Income ("GILTI"), as defined in the Tax Cuts and Jobs Act of 2017, generated from our non-U.S. operations is subject to U.S. taxes, with certain defined exemptions, thresholds and credits. For financial reporting purposes the Company has elected to treat GILTI inclusions as a period cost.

For the three months ended September 30, 2025, the Company recognized an income tax expense of \$7.2 million. The Company's effective tax rate was 21.3% after discrete items for the three months ended September 30, 2025. The effective tax rate differed from the federal statutory rate of 21% primarily due to excess tax benefits recognized upon settlement of stock-based compensation and non-taxable adjustments to the fair value of certain contingent liabilities related to the acquisition of Alimera.

For the three months ended September 30, 2024, the Company recognized an income tax benefit of \$7.3 million. The Company's effective tax rate was 23.3% after discrete items for the three months ended September 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, and non-deductible expenses related to the 2024 acquisition of Alimera.

For the nine months ended September 30, 2025, the Company recognized an income tax expense of \$13.5 million. The Company's effective tax rate was 20.9% after discrete items for the nine months ended September 30, 2025. The effective tax rate differed from the federal statutory rate of 21% primarily due to excess tax benefits recognized upon settlement of stock-based compensation, favorable return to provision adjustments attributable to certain foreign tax returns filed during the period, and non-taxable adjustments to the fair value of certain contingent liabilities related to the acquisition of Alimera.

For the nine months ended September 30, 2024, the Company recognized an income tax benefit of \$0.2 million. The Company's effective tax rate was 2.4% after discrete items for the nine months ended September 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, tax on the sale of the Oakville, Ontario manufacturing site, and recording of a withholding tax liability on the proceeds of the sale, and non-deductible expenses related to the 2024 acquisition of Alimera.

On July 4, 2025, the U.S. government enacted the One Big Beautiful Bill Act ("OBBBA"), which includes several changes to U.S. federal income tax law, including the temporary and permanent extension, of expiring provisions of the Tax Cuts and Jobs Act of 2017. There was not a significant impact to the Company's income tax expense or effective tax rate for the three and nine months ended September 30, 2025 as a result of the OBBBA.

## 15. COMMITMENTS AND CONTINGENCIES

### Operating Leases

The majority of the Company's leases as of September 30, 2025 are classified as operating leases. Leases with an initial term of twelve months or less are not recorded on the balance sheet, and the Company does not separate lease and non-lease components of contracts. The Company's lease agreements do not provide for determination of the interest rate implicit in the lease. Therefore, the Company used a benchmark approach to derive an appropriate incremental borrowing rate. The Company's incremental borrowing rate is the rate of interest that the lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company benchmarked itself against other companies of similar credit ratings and comparable quality and derived an incremental borrowing rate, which was used to discount its lease liabilities. Rent expense is recognized on a straight-line basis over the lease term. Operating lease ROU assets are included in other non-current assets and operating lease liabilities are included in accrued expenses and other and other non-current liabilities in the unaudited condensed consolidated balance sheets. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The Company entered into a new lease agreement for office space located in Princeton, New Jersey, for a term of approximately 10 years, following the lease commencement date of August 18, 2025. The office space serves as the Company's commercial headquarters, which includes certain employees in the the Company's corporate, legal, human resources, business functions, and commercial operations. The Company recognized a right-of-use asset and a corresponding lease liability at the lease commencement date of approximately \$5.2 million. The lease liability is initially measured at the present value of the lease payments, discounted using the lessee's incremental borrowing rate of approximately 7.4%. The lease agreement includes a rent-free period of three months, and is classified as an operating lease in the unaudited condensed consolidated balance sheets.

### Finance Leases

In connection with the acquisition of Alimera, the Company acquired finance leases primarily consisting of automobiles. The automobiles are capitalized at the lesser of fair market value or the present value of the minimum lease payments at the inception of the leases using the Company's incremental borrowing rate. The Company's finance lease agreements do not contain any material residual value guarantees or material restrictive covenants. Finance lease ROU assets are included in other non-current assets, specifically in Property and equipment, net, and finance lease liabilities are included in accrued expenses and other and other non-current liabilities in the unaudited condensed consolidated balance sheets.

### Government Regulation

The Company's products and facilities are subject to regulation by a number of federal and state governmental agencies, such as the Drug Enforcement Administration ("DEA"), the FDA, the Centers for Medicare and Medicaid Services ("CMS"), the Central Drugs Standard Control Organization ("CDSCO"), The Narcotics Control Bureau ("NCB"), and India's Ministry of Health and Family Welfare ("MoHFW"). The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of ANI's products. The DEA and NCB maintain oversight over products that are considered controlled substances.

### Unapproved Products

Four products, Esterified Estrogens and Methyltestosterone ("EEMT"), Opium Tincture, Thyroid Tablets, and Hyoscyamine are sold without approved NDAs or ANDAs. If the FDA took enforcement action against the Company, the Company may be required to seek FDA approval for the group of products or withdraw them from the market. During the three and nine months ended September 30, 2025, net revenues from commercial sales of these products totaled \$6.0 million and \$17.6 million, respectively. During the three and nine months ended September 30, 2024, net revenues from commercial sales of these products totaled \$5.5 million and \$16.4 million, respectively.

## Legal proceedings

The Company is involved, and from time to time may become involved, in various disputes, governmental and/or regulatory inquiries, investigations, government reimbursement related actions and litigation. These matters are complex and subject to significant uncertainties. While the Company believes that it has valid claims and/or defenses in the litigation and other matters described below, litigation is inherently unpredictable, particularly where the damages sought are substantial or indeterminate or when the proceedings, investigations or inquiries are in the early stages, and the outcome of the proceedings could result in losses, including substantial damages, fines, civil or criminal penalties and injunctive or administrative remedies. The Company intends to vigorously prosecute and/or defend these matters, as appropriate; however, from time to time, the Company may settle or otherwise resolve these matters on terms and conditions that it believes are in the Company's best interests. Resolution of any or all claims, investigations, and legal proceedings, individually or in the aggregate, could have a material adverse effect on our results of operations and/or cash flows in any given accounting period or on our overall financial condition.

Unless otherwise disclosed, the Company is unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. The Company records accruals for loss contingencies to the extent it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

From time to time, the Company may also be involved in other pending proceedings for which, in our opinion based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to our results, and therefore remain undisclosed. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in our opinion, become material, the Company will disclose such matters.

Furthermore, like many pharmaceutical manufacturers, the Company is periodically exposed to product liability claims. The prevalence of these claims could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results. Recent trends in the product liability and director and officer insurance markets is to exclude matters related to certain classes of drugs. Our policies have been subject to such exclusions which place further potential risk of financial loss on us.

Legal fees for litigation-related matters are expensed as incurred and included in the unaudited condensed consolidated statements of operations under the selling, general, and administrative expense line item.

### *Commercial Litigation*

On March 4, 2024, ANI commenced a civil action against CG Oncology, Inc. f/k/a Cold Genesys, Inc. ("CG Oncology") in the Superior Court of the State of Delaware ("Delaware Action"). ANI's complaint alleges that, under an Assignment and Technology Transfer Agreement dated as of November 15, 2010 (the "November 2010 Agreement"), CG Oncology is liable to pay ANI a running royalty of 5% of the worldwide net sales of cretostimogene made by CG Oncology or any affiliate or sublicensee thereof, and that in February 2024, CG Oncology wrongfully repudiated its royalty obligation to ANI. On April 2, 2024, CG Oncology filed an answer and counterclaim (the "CGON Answer and Counterclaim") and concurrently moved for judgment on the pleadings or, in the alternative, for partial summary judgment (the "Motion for Summary Judgment"). CG Oncology's Motion for Summary Judgment sought judgment declaring that the November 2010 Agreement does not "oblige CGON to pay royalties after expiration of the latest-running assigned patent." On April 25, 2024, ANI filed a reply to CG Oncology's counterclaims, denying any liability to CG Oncology and asserting additional counterclaims against CG Oncology ("Reply Counterclaims") for alleged breach of the November 2010 Agreement and, in the alternative, for unjust enrichment. On May 15, 2024, CG Oncology filed a reply to ANI's counterclaims, denying any liability to ANI and generally maintaining the positions taken in the CGON Answer and Counterclaim. On November 18, 2024, the court denied CG Oncology's Motion for Summary Judgment. On June 2, 2025, CG Oncology filed five motions for summary judgment seeking dismissal of all of ANI's claims and counterclaims, including breach of the royalty payment provision, breach of good faith performance, breach of the implied covenant of good faith, and in the alternative, unjust enrichment. Also on June 2, 2025, ANI filed a motion for partial summary judgment seeking dismissal of CG Oncology's counterclaims for unenforceability of the royalty payment provision under *Brulotte*, breach of good faith performance, breach of confidentiality and trade secret misappropriation. At a pretrial conference on July 16, 2025, the court granted CG Oncology's motion for partial summary judgment on its *Brulotte* counterclaim and affirmative defense, but allowed the case to proceed on ANI's counterclaim for unjust enrichment. The court also granted ANI's motion for partial summary judgment, dismissing CG Oncology's breach of confidentiality and trade secret misappropriation claims. The jury trial commenced in Delaware Superior Court on July 21, 2025. On July 29, 2025, a verdict was returned by the jury, finding that (1) the unenforceability of the royalty payment provision in the November 2010 Agreement did not affect the economic or legal substance of the transactions contemplated thereby in a manner that was materially adverse to ANI, and (2) awarding no damages to ANI on its unjust enrichment counterclaim. On August 12, 2025, ANI filed a motion for a new trial and for judgment as a matter of law.

On September 10, 2025, CG Oncology filed its opposition to ANI's motion, and on October 8, 2025, ANI filed its reply to CG Oncology's opposition. A hearing date has not yet been scheduled by the court. ANI expects to continue to challenge this verdict through post-trial motions and/or an appeal.

On March 6, 2024, a complaint was filed against ANI by Acella Pharmaceuticals, LLC, in the United States District Court of Minnesota, asserting, among other things, false advertising under the Lanham Act, and unfair trade practices and false advertising under Minnesota law, relating to ANI's natural desiccated thyroid tablets USP. The complaint seeks injunctive relief, actual and consequential damages, disgorgement of profits, and attorneys' fees and costs. On April 16, 2024, ANI filed an answer to Acella's complaint, denying all claims, and asserting certain affirmative defenses, and counterclaims against Acella for false advertising of its thyroid product marketed as NP Thyroid® Tablets, under the Lanham Act, common law unfair competition and unfair and deceptive trade practices and false advertising under Minnesota and Georgia law. ANI seeks injunctive relief, compensatory damages, punitive damages and attorneys' fees and costs. On May 17, 2024, Acella filed a motion to dismiss ANI's counterclaims. On June 7, 2024, ANI filed an amended answer to Acella's complaint and counterclaims. Acella filed a motion to dismiss ANI's amended counterclaims on July 31, 2024. A hearing was held on September 11, 2024 on Acella's motion to dismiss. On December 19, 2024, the court issued an order denying Acella's motion. The parties have been unable to reach a settlement to date. Fact discovery is currently scheduled to close on November 21, 2025 and expert discovery is currently scheduled to close on February 18, 2026. The trial-ready date is currently set for no earlier than August 2026. ANI disputes any liability in this matter and intends to defend this lawsuit vigorously.

### ***Patent Litigation***

On November 21, 2023, a complaint was filed against Novitium and certain other defendants in the case of Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche and Bioprojet Pharma SAS v. AET Pharma US, Inc., Annora Pharma Private Limited, Novitium Pharma LLC, Zenara Pharma Private Limited and Biophore India Pharmaceuticals Private Limited in the United States District Court for the District of Delaware, asserting, among other things, that Novitium's proposed pitolisant hydrochloride drug product, which is subject to Novitium's Abbreviated New Drug Application, infringes certain U.S. patents owned by the plaintiffs. The complaint seeks damages, injunctive relief, attorneys' fees and costs. On January 29, 2024, Novitium filed its answer, denying all allegations and asserting counterclaims of non-infringement and invalidity. On February 16, 2024, plaintiffs filed their answer, denying Novitium's counterclaims and asserting certain affirmative defenses against Novitium. On April 15, 2024, the court consolidated Novitium's case and two other cases brought by plaintiffs against Lupin Limited et al, and MSN Pharms. Inc. et al., into one consolidated matter filed in C.A. No. 23-1286-JLH. Fact discovery closed on April 18, 2025 and expert discovery is scheduled to close on November 25, 2025. The court set a trial date for February 2026. Novitium disputes any liability in this matter.

On December 27, 2024, a complaint was filed against Novitium by Athena Bioscience, LLC ("Athena") in the United States District Court for the District of Delaware, asserting, among other things, that Novitium's proposed tramadol hydrochloride solution drug product, which is subject to Novitium's Abbreviated New Drug Application, infringes certain U.S. patents owned by Athena. The complaint seeks damages, injunctive relief, attorneys' fees and costs. On March 7, 2025, Novitium filed its answer, denying all allegations and asserting counterclaims of non-infringement and invalidity. On March 28, 2025, Athena filed its answer to Novitium's answer and counterclaims. On September 4, 2025, Athena and Novitium jointly filed a Stipulation and Order of Dismissal of all claims, counterclaims and defenses, which order was entered by the court on September 8, 2025, effectively terminating the case.

## ***Ranitidine Related Litigation***

### ***Federal Court Multi District Litigation***

ANI and Novitium were named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in *In re: Zantac/Ranitidine NDMA Litigation* (MDL No. 2924), filed in the United States District Court for the Southern District of Florida (the “MDL Court”). Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or “NDMA”) in brand-name Zantac or generic ranitidine and the alleged associated risk of cancer. While ANI was initially a defendant, the lead plaintiff attorneys voluntarily dismissed ANI as a defendant in the Master Complaint. On July 8, 2021, the MDL Court dismissed all claims by all plaintiffs against the generic drug manufacturers with prejudice, on preemption grounds. The MDL Court also dismissed all claims by all plaintiffs against the brand manufacturers on summary judgment. Plaintiffs appealed the MDL Court’s dismissals to the Eleventh Circuit Court of Appeals. On November 7, 2022, the Eleventh Circuit affirmed the MDL Court’s dismissal of cases brought by third-party payors. The Eleventh Circuit raised questions in the appeals of the other cases about the finality of the MDL Court’s judgments, which were resolved in September 2023. Plaintiffs filed opening briefs on April 10, 2024 and generics defendants filed their response on July 25, 2024. Plaintiffs filed reply briefs in September 2024. Oral arguments were heard on October 10, 2025 and a decision from the court is pending.

ANI and Novitium dispute any liability in this matter.

### ***State Court Personal Injury Litigation***

ANI and Novitium have also been named as defendants in various state lawsuits.

*California.* The pending cases in California state court naming generic ranitidine manufacturers were transferred to an existing civil case coordination docket for pretrial proceedings (JCCP) in Alameda County. On September 21, 2023, plaintiffs filed a master complaint in the JCCP alleging strict liability, negligent failure to warn and general negligence, but not naming any generic defendants. Plaintiffs filed an amended master complaint on April 29, 2024 and filed a second amended master complaint on July 2, 2024. Defendants filed omnibus demurrers to the complaint. Novitium is currently named in one bellwether case (Bautista), one wave 2 case (Austin), one wave 3 case (Rodarte), three wave 5 cases, six wave 6 cases, and four wave 7 cases. Discovery has commenced on the first four waves. The court heard arguments for the demurrers on August 22, 2024 and issued its final ruling on August 28, 2024, allowing some counts to survive. The surviving counts as to generic defendants include strict liability (manufacturing defect) and general negligence (storage and transport, failure to warn and product containers). Novitium filed its answer to the second amended master complaint on September 6, 2024.

In December 2023, the Keller Postman firm filed a large number of short form complaints that name generic defendants. Novitium is named in 29 of the short form complaints which reference the claims for the master complaint, but Novitium has not been served. ANI is not named. On February 1, 2024, the generic defendants filed an omnibus demurrer challenging the sufficiency of the Keller Postman complaints, largely on the basis of preemption. On April 23, 2024, the California court sustained the demurrer in part, dismissing all design defect claims against the generic defendants with prejudice on preemption grounds, but the court otherwise granted plaintiffs an opportunity for leave to amend their other claims against the generic defendants. Plaintiffs filed amended short form complaints on September 20, 2024 and defendants filed responses on October 6, 2024. No case including Novitium is expected to go to trial before January 2026.

*Pennsylvania.* In September 2022, two complaints were filed naming Novitium as a defendant in Pennsylvania state court, Philadelphia County. On February 16, 2023, the Pennsylvania plaintiffs filed a consolidated long-form complaint against the generic defendants, *Plaintiffs v. Actavis, et. al.* Civil Action No. 1364. The long-form complaint names Novitium as a defendant. The long form complaint asserts causes of action for negligence, failure to warn, negligent storage and transportation, breach of express warranties, breach of implied warranties, negligent misrepresentation, fraud, strict products liability, wrongful death and survivor actions, and loss of consortium. The complaint includes a prayer for punitive damages. The generic defendants filed their preliminary objections to Plaintiffs’ consolidated long-form generic complaint on March 20, 2023. The court dismissed all claims related to failure to warn/design defects on preemption grounds. The court also sustained the generics’ preliminary objections relating to the counts of strict liability-design defect and breach of implied warranty to the extent Pennsylvania substantive law applies, effectively dismissing the generic defendants from the case unless and until a non-resident plaintiff names a generic in a short form complaint. Out of an abundance of caution, however, the generics, including Novitium, all filed answers to the long form complaint in June 2023. In January 2024, plaintiffs filed short form complaints naming generic defendants, including naming Novitium in one complaint filed by William Titus. Generic defendants filed joint preliminary objections to the short form complaints based on preemption. The deadline for filing responses to these objections has passed. The Titus complaint was subsequently amended and Novitium was not named in the amended short form complaint or in any other amended short form complaint filed by plaintiffs.

ANI and Novitium dispute any liability in these matters.

## 16. FAIR VALUE

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.

The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of our funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities) approximate their carrying values because of their short-term nature. The New Credit Facility bears an interest rate that fluctuates with the changes in SOFR and because the variable interest rate approximates market borrowing rates available to the Company, the carrying value of the New Credit Facility approximated its fair value at September 30, 2025.

### Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

#### *Alimera Contingent Value Rights Agreement*

On September 16, 2024, prior to consummation of the Alimera Acquisition, the Company entered into a CVR pursuant to which holders of Alimera Common Stock, as well as holders of Alimera Warrants, Alimera Options, Alimera PSUs, Alimera RSAs and Alimera RSUs, may become entitled to contingent cash payments per CVR (each, a “Milestone Payment”), such payments being contingent upon, and subject to, the achievement of: (i) \$140.0 million in net revenue (the “2026 Milestone”) on third party sales of ILUVIEN and YUTIQ for the Company’s 2026 fiscal year (the “2026 Net Revenue”) and/or (ii) \$160.0 million in net revenue (the “2027 Milestone” and together with the 2026 Milestone, the “Milestones”) on third party sales of ILUVIEN and YUTIQ for the Company’s 2027 fiscal year (the “2027 Net Revenue”). Each CVR entitles the holder (the “Holder”) to receive a Milestone Payment upon satisfaction of the applicable Milestones. The Milestone Payment for each CVR will equal the product (rounded to the nearest 1/100 of \$0.01) of (i) \$0.25 multiplied by a fraction (not exceeding one), the numerator of which is the amount, if any, by which the 2026 Net Revenue exceeds \$140.0 million and the denominator of which is \$10.0 million (subject to adjustment for the exercise price of applicable Alimera Options) and/or (ii) \$0.25 multiplied by a fraction (not exceeding one), the numerator of which is the amount, if any, by which the 2027 Net Revenue exceeds \$160.0 million and the denominator of which is \$15.0 million (subject to adjustment for the exercise price of applicable Alimera Options).

If a Milestone is attained, the distributions in respect of the CVRs will be made on or prior to the date that is fifteen (15) business days following the filing by the Company of its audited financial statements with the SEC on Form 10-K in respect of the applicable year in which such Milestone has been achieved, and will be subject to a number of deductions, exceptions and limitations, including, but not limited to, certain taxes.

The fair value of the CVR liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The Company utilizes a Monte Carlo simulation model to estimate the fair value of the CVR liability. For each simulated path of future revenue, the payments to the CVR holders were calculated based on the contractual terms of the rights. The average payments from all simulated paths are then discounted to present value at an estimated cost of debt. The CVR liability had an estimated fair value of \$3.5 million as of September 30, 2025, and is classified as non-current contingent consideration in the Company's unaudited condensed consolidated balance sheet.

The following table presents the changes in the CVR liability classified as Level 3 for the three and nine months ended September 30, 2025 and 2024:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Beginning balance	\$ 6,000	\$ —	\$ 9,000	\$ —
Change in fair value	(2,523)	8,700	(5,523)	8,700
Ending balance	\$ 3,477	\$ 8,700	\$ 3,477	\$ 8,700

### ***Money Market Funds***

Money market funds are readily convertible into cash and the net asset value of each fund on the last day of the reporting period is used to determine its fair value. Money market funds are included in Cash and cash equivalents within the unaudited condensed consolidated balance sheet, and is classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the money market funds as of September 30, 2025 was approximately \$168.0 million.

### ***Interest Rate Swap***

The fair value of the interest rate swap is estimated based on the present value of projected future cash flows using the SOFR forward rate curve (see Note 6 “New Credit Agreement” to the notes to the condensed consolidated financial statements (unaudited)). The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in further detail in Note 8 “Derivative Financial Instrument and Hedging Activity” to the notes to the condensed consolidated financial statements (unaudited). The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in further detail in Note 8, the fair value of the interest rate swap was \$2.2 million as of September 30, 2025, and was classified as a non-current asset.

### ***CG Oncology Equity Securities***

The Company currently holds 219,925 shares of common stock in CG Oncology (Nasdaq: CGON). The Company accounts for its investment in CG Oncology equity securities as an equity investment with a readily determinable fair value, as the securities are publicly traded on the Nasdaq Global Select Market. The fair value of the equity securities is based on its closing price on the Nasdaq and is classified within Level 1 of the fair value hierarchy because the equity securities are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the CG Oncology equity securities as of September 30, 2025 was approximately \$8.9 million based on a closing market price of \$40.28 on September 30, 2025. The change in fair value of the equity securities is classified on the unaudited condensed consolidated statements of operations as unrealized (loss) gain on investment in equity securities for the three and nine months ended September 30, 2025 and 2024. Between 2013 and 2023, CG Oncology securities held by the Company were valued at zero under U.S. GAAP.

### ***Novitium Contingent Consideration***

In connection with the acquisition of Novitium, the Company may pay up to \$46.5 million in additional consideration related to the achievement of certain milestones, such as milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future.

The discounted cash flow method used to value this contingent consideration includes inputs which are classified as Level 3 inputs, as the inputs are not based on readily available market data.

In connection with the terms of the Novitium Merger Agreement, on December 12, 2023, the Company paid \$12.5 million of cash consideration to the Company Members, defined as the holders of Novitium ownership interests in the Novitium Merger Agreement, as the holders of Novitium ownership interests, for the achievement of the “ANDA Filing Earn-Out,” as defined in the Agreement (Note 15 “Commitments and Contingencies” to the notes to the condensed consolidated financial statements (unaudited)). Furthermore, on February 22, 2024, the Company paid \$12.5 million to Company Members upon the achievement of the “Gross Profit Earn-Out,” as defined in the Agreement (Note 17 “Related Party Transactions” to the notes to the condensed consolidated financial statements (unaudited)).

In accordance with the terms of the Novitium Merger Agreement, the Company shall owe 20% of net profit generated by the sales of the 505(b)(2) products, to the Company Members, as defined within the agreement. The payments are due on a quarterly basis, within 45 calendar days of each quarter end, until the earlier to occur of (i) the sum of all such payments being equal to \$21.5 million in the aggregate and (ii) the tenth anniversary of the FDA approval of the applicable 505(b)(2) product (the “505(b)(2) Earn-Out”). During the three months ended September 30, 2025, the Company has paid approximately \$26 thousand for payment of the 505(b)(2) Earn-Out to the Company Members.

The fair value of the contingent consideration was approximately \$8.0 million and \$10.9 million as of September 30, 2025 and December 31, 2024, respectively, and is reflected as a current and non-current accrued contingent consideration liability in the unaudited condensed consolidated balance sheets.

The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs as of September 30, 2025:

Payment Type	Valuation Technique	Unobservable Input	Assumptions
Profit-based milestone payments	Probability-weighted discounted cash flow	Discount rate	12.0%
		Projected fiscal years of payments	2025-2034

The following table presents the changes in contingent consideration balances classified as Level 3 for the three and nine months ended September 30, 2025 and 2024:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Beginning balance	\$ 12,572	\$ 11,933	\$ 10,854	\$ 23,984
Payment of Gross-Profit earn-out	(26)	—	(26)	(12,500)
Change in fair value	(4,581)	825	(2,863)	1,274
Ending balance	\$ 7,965	\$ 12,758	\$ 7,965	\$ 12,758

#### Accrued Licensor Payments

On May 17, 2023, Alimera entered into a product rights agreement with EyePoint which granted Alimera an exclusive and sublicensable right and license under EyePoint's and its affiliates' interest in certain of EyePoint's and its affiliates' intellectual property to develop, manufacture, sell, commercialize and otherwise exploit certain products, including YUTIQ, for the treatment and prevention of uveitis in the entire world, except Europe, the Middle East and Africa, where the Company already has such rights pursuant to the New Collaboration Agreement, and except for China, Hong Kong, Macau, Taiwan, Brunei, Burma (Myanmar), Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, South Korea, Thailand and Vietnam, where Ocumension holds a license from EyePoint. Pursuant to the agreement, Alimera paid EyePoint an upfront payment of \$75.0 million and has also made four quarterly guaranteed payments to EyePoint totaling \$7.5 million during the year ended December 31, 2024.

The Company will also pay royalties to EyePoint from 2025 to 2028 at 30% of annual U.S. net sales of certain products (including YUTIQ and ILUVIEN) in excess of certain thresholds, beginning at \$70.0 million in 2025, increasing annually thereafter. Upon making the quarterly payments in the aggregate amount of \$7.5 million in 2024, the licenses and rights granted to the Company will automatically become perpetual and irrevocable.

For the quarter ended December 31, 2024, the Company paid the final quarterly payment of \$1.9 million. The present value of the remaining payments to EyePoint for years 2025 to 2028 will continue to be revalued at an appropriate discount rate for the Company at each reporting date until payments are settled. The fair value of the remaining future payments as of September 30, 2025 was approximately \$4.1 million.

The recurring Level 3 fair value measurements of the EyePoint royalty for which a liability is recorded include the following significant unobservable inputs as of September 30, 2025:

Payment Type	Valuation Technique	Unobservable Input	Assumptions
Annual royalty payments for US net revenues of sales of YUTIQ and ILUVIEN	Probability-weighted discounted cash flow	Discount rate	11.5%
		Projected fiscal year of payment	2028-2029

The following table presents the changes in accrued licensor payments classified as Level 3 balances for the three and nine months ended September 30, 2025 and 2024:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Beginning balance	\$ 11,428	\$ —	\$ 20,961	\$ —
Change in fair value	(7,366)	—	(16,899)	—
Ending balance	\$ 4,062	\$ —	\$ 4,062	\$ —

The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of September 30, 2025 and December 31, 2024, by level within the fair value hierarchy:

(in thousands) Description	Fair Value at September 30, 2025	Level 1	Level 2	Level 3
<b>Assets</b>				
Money Market Fund	\$ 167,977	\$ 167,977	\$ —	\$ —
Interest rate swap	\$ 2,232	\$ —	\$ 2,232	\$ —
CG Oncology - Investment in equity securities	\$ 8,859	\$ 8,859	\$ —	\$ —
<b>Liabilities</b>				
Contingent consideration, Novitium	\$ 7,965	\$ —	\$ —	\$ 7,965
Contingent Value Rights, Alimera	\$ 3,477	\$ —	\$ —	\$ 3,477
Accrued licensor payment	\$ 4,062	\$ —	\$ —	\$ 4,062

Description	Fair Value at December 31, 2024	Level 1	Level 2	Level 3
<b>Assets</b>				
Money Market Fund	\$ 84,277	\$ 84,277	\$ —	\$ —
Interest rate swap	\$ 4,897	\$ —	\$ 4,897	\$ —
CG Oncology - Investment in equity securities	\$ 6,307	\$ 6,307	\$ —	\$ —
<b>Liabilities</b>				
Contingent consideration, Novitium	\$ 10,854	\$ —	\$ —	\$ 10,854
Contingent Value Rights, Alimera	\$ 9,000	\$ —	\$ —	\$ 9,000
Accrued licensor payment	\$ 20,961	\$ —	\$ —	\$ 20,961

#### Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

There are no financial assets or liabilities that are measured at fair value on a non-recurring basis.

#### Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

There are no non-financial assets or liabilities that are measured at fair value on a recurring basis.

#### Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

Long-lived assets, including property, plant, and equipment, right-of-use (“ROU”) assets, intangible assets, and goodwill, are measured at fair value on a non-recurring basis, and no such fair value impairment was recognized in the three and nine months ended September 30, 2025 and 2024.

## 17. RELATED PARTY TRANSACTIONS

### *PIPE Shares*

On March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which 25,000 PIPE Shares were purchased for \$1,000 per share for an aggregate purchase price of \$25.0 million on November 19, 2021. The Chairman of the Company's board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor.

During the third quarter of 2025, all of the PIPE Shares were converted to common shares of the Company, and there were no PIPE Shares outstanding as of September 30, 2025. Refer to Note 12 "Mezzanine and Stockholders' Equity" to the notes to the condensed consolidated financial statements (unaudited) for further information related to the conversion of the PIPE Shares.

### *Novitium*

In connection with the acquisition of Novitium, the Company entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam, Head of R&D and COO of NJ Operations of ANI, and Chad Gassert, Sr. Vice President, Corporate Development and Strategy of ANI. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Company's Board of Directors. Mr. Shanmugam and Mr. Gassert hold a minority interest in Scitus Pharma Services Private Limited ("Scitus"), which provides clinical research services to Novitium. Mr. Shanmugam holds a majority interest in SS Pharma LLC ("SS Pharma"), which acquires and supplies API to Novitium, a minority interest in Nuray Chemical Private Limited ("Nuray"), which manufactured and supplied API to Novitium in prior periods, a majority interest in Esjay Pharma Private Limited and Esjay LLC (collectively "Esjay"), which provides research and development, certain finished goods, certain consulting services, and a minority interest in SThree Chemicals Pvt Ltd and SThree Chemicals LLC (collectively "SThree"), which acquires and supplies API to Novitium.

A summary of payments to related parties is presented below:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Scitus	\$ 217	\$ 1,155	\$ 2,149	\$ 2,236
SS Pharma	—	—	—	1,245
SThree	2,381	4,214	6,711	5,283
Esjay	2,485	79	2,934	79
Total payments	\$ 5,083	\$ 5,448	\$ 11,794	\$ 8,843

As of September 30, 2025, the outstanding balances due to Scitus, Esjay, and SThree were \$1.7 million, \$0.9 million, and \$0.3 million, respectively. There was no outstanding balance due to SS Pharma and Nuray.

On February 22, 2024, the Company paid \$12.5 million of cash consideration to the Company Members of Novitium for the achievement of the "Gross Profit Earn-Out," as defined in the Novitium Merger Agreement. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert's company, Chali Properties LLC, approximately \$6.7 million and \$1.9 million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.

## 18. SEGMENT REPORTING

An operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entity's chief operating decision maker ("CODM") to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. The CODM for the Company is the Chief Executive Officer. The Company does not aggregate its operating segments for reporting purposes, and therefore, the reportable segments are the same as its operating segments.

Following the acquisition of Alimera and during the fourth quarter of 2024, the Company reorganized the segment information that is regularly provided to the chief operating decision maker which caused the identification of significant segment expenses to change. Therefore, the Company recasted prior period segment information to conform to the current-period presentation in accordance with the segment guidance at ASC 280-10-50-34.

The Company is now organized into two operating segments as follows:

- **Rare Disease and Brands** – Consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing and marketing of proprietary branded pharmaceutical products, with a strategic focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN (there were no sales of YUTIQ during the quarter ended September 30, 2025). In addition, the Brands reporting unit includes a portfolio of approximately 20 brand products that are principally sold in highly genericized markets.
- **Generics and Other** – Consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and other. As of September 30, 2025, this reporting segment was comprised of over 100 product families.

The CODM evaluates the performance of the Company as two operating segments based on revenues and Operating income (loss), exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to; certain management, legal, accounting, human resources, insurance, information technology expenses, and transaction and integration expenses related to the acquisition of Alimera and other acquisitions.

The Company does not manage assets of the Company by operating segment and the CODM does not review asset information by operating segment. Accordingly, the Company does not present total assets by operating segment.

Financial information by reportable segment is as follows:

	Three Months Ended September 30, 2025			
	Generics and Other	Rare Disease and Brands	Corporate and Unallocated	Total
Net Revenues	\$ 98,688	\$ 129,125	\$ —	\$ 227,813
Less:				
Cost of sales (excluding depreciation and amortization)	53,736	39,653	—	93,389
Research and development	8,472	3,832	—	12,304
Selling, general, and administrative	1,405	43,983	31,268	76,656
Depreciation and amortization	—	—	22,632	22,632
Contingent consideration fair value adjustment	—	—	(14,470)	(14,470)
Loss on disposal of assets	—	—	295	295
Intangible asset impairment charge	—	—	767	767
Operating Income (Loss)	\$ 35,075	\$ 41,657	\$ (40,492)	\$ 36,240
Unrealized gain on investment in equity securities	\$ —	\$ —	\$ 3,140	\$ 3,140
Interest expense, net	—	—	(4,727)	(4,727)
Other expense, net	—	—	(853)	(853)
Income (Loss) Before Income Tax Expense	\$ 35,075	\$ 41,657	\$ (42,932)	\$ 33,800

**Three Months Ended September 30, 2024**

	<b>Generics and Other</b>	<b>Rare Disease and Brands</b>	<b>Corporate and Unallocated</b>	<b>Total</b>
Net Revenues	\$ 82,711	\$ 65,621	\$ —	\$ 148,332
Less:				
Cost of sales (excluding depreciation and amortization)	42,585	20,490	—	63,075
Research and development	6,123	4,005	—	10,128
Selling, general, and administrative	1,384	35,705	41,986	79,075
Depreciation and amortization	—	—	15,748	15,748
Contingent consideration fair value adjustment	—	—	825	825
Operating (Loss) Income	\$ 32,619	\$ 5,421	\$ (58,559)	\$ (20,519)
Unrealized gain on investment in equity securities	\$ —	\$ —	\$ 1,355	\$ 1,355
Interest expense, net	—	—	(2,331)	(2,331)
Other expense, net	—	—	(2,535)	(2,535)
Loss on extinguishment of debt	—	—	(7,468)	(7,468)
Income (Loss) Before Income Tax Benefit	\$ 32,619	\$ 5,421	\$ (69,538)	\$ (31,498)

**Nine Months Ended September 30, 2025**

	<b>Generics and Other</b>	<b>Rare Disease and Brands</b>	<b>Corporate and Unallocated</b>	<b>Total</b>
Net Revenues	\$ 295,941	\$ 340,365	\$ —	\$ 636,306
Less:				
Cost of sales (excluding depreciation and amortization)	143,468	97,573	—	241,041
Research and development	26,474	12,929	—	39,403
Selling, general, and administrative	4,202	137,610	93,143	234,955
Depreciation and amortization	—	—	68,804	68,804
Contingent consideration fair value adjustment	—	—	(25,285)	(25,285)
Loss on disposal of assets	—	—	295	295
Intangible asset impairment charge	—	—	767	767
Operating Income (Loss)	\$ 121,797	\$ 92,253	\$ (137,724)	\$ 76,326
Unrealized gain on investment in equity securities	\$ —	\$ —	\$ 2,551	\$ 2,551
Interest expense, net	—	—	(15,649)	(15,649)
Other income, net	—	—	1,084	1,084
Income (Loss) Before Income Tax Expense	\$ 121,797	\$ 92,253	\$ (149,738)	\$ 64,312

	<b>Nine Months Ended September 30, 2024</b>			
	<b>Generics and Other</b>	<b>Rare Disease and Brands</b>	<b>Corporate and Unallocated</b>	<b>Total</b>
Net Revenues	\$ 236,346	\$ 187,456	\$ —	\$ 423,802
Less:				
Cost of sales (excluding depreciation and amortization)	121,399	48,531	—	169,930
Research and development	19,569	8,366	—	27,935
Selling, general, and administrative	3,737	86,720	89,460	179,917
Depreciation and amortization	—	—	45,131	45,131
Contingent consideration fair value adjustment	—	—	1,274	1,274
Gain on sale of building	—	—	(5,347)	(5,347)
Operating Income (Loss)	\$ 91,641	\$ 43,839	\$ (130,518)	\$ 4,962
Unrealized gain on investment in equity securities	\$ —	\$ —	\$ 8,298	\$ 8,298
Interest expense, net	—	—	(11,587)	(11,587)
Other expense, net	—	—	(2,655)	(2,655)
Loss on extinguishment of debt	—	—	(7,468)	(7,468)
Income (Loss) Before Income Tax Benefit	\$ 91,641	\$ 43,839	\$ (143,930)	\$ (8,450)

## Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

*The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the condensed consolidated financial statements (unaudited) and the accompanying notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, the audited consolidated financial statements and the accompanying notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”), as well as the information contained under Management’s Discussion and Analysis of Financial Condition and Results of Operations and “Risk Factors” contained in the 2024 Form 10-K, and Part II, Item 1A “Risk Factors” of this Quarterly Report on Form 10-Q, and other information provided from time to time in our other filings with the SEC. This discussion contains forward-looking statements, based on current expectations and related to future events and our future financial performance, that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many important factors, including those set forth under “Risk Factors” in our 2024 Form 10-K and this Quarterly Report on Form 10-Q.*

### EXECUTIVE OVERVIEW

ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, “ANI,” the “Company,” “we,” “us,” or “our”) is a diversified bio-pharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high quality therapeutics.

On September 16, 2024, the Company completed its previously announced acquisition of Alimera Sciences, Inc., a Delaware corporation, pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the “Merger Agreement”), by and among the Company, Alimera and ANIP Merger Sub INC., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub merged with and into Alimera, with Alimera surviving the merger as a wholly owned subsidiary of the Company (the “Merger”). In connection with the Merger, the Company added a growing and durable franchise, ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, which has received marketing authorization and reimbursement in the United States (“U.S.”) and 24 countries for the treatment of diabetic macular edema (“DME”) and YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, available in the U.S. for the treatment of non-infectious uveitis affecting the posterior segment of the eye (“NIU-PS”). Subsequent to the acquisition of Alimera, we expanded the label for ILUVIEN to include an indication for chronic NIU-PS in addition to its then current indication in DME in the U.S., refer below for further information related to the expanded label.

Our three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment.

### **Strategy**

Our objective is to build a sustainable and growing biopharmaceutical company serving patients in need and creating long-term value for our investors. Our overall strategy is enabled by an empowered, collaborative, and purposeful team with high performance-orientation that seeks to deliver on our purpose of “Serving Patients, Improving Lives.”

Our strategy is driven by the following key growth drivers:

### ***Building a successful Rare Disease and Brands Segment***

We spend significant time, effort and resources in establishing and expanding our Rare Disease and Brands segment which consists of our Rare Disease and Brands portfolio of products.

We acquired the NDAs for Purified Cortrophin® Gel (Repository Corticotropin Injection USP) (“Cortrophin Gel”) and Cortrophin-Zinc™ in January 2016 and executed long-term supply agreements with a supplier of our primary raw material for corticotrophin API, a supplier of corticotrophin API with whom we have advanced the manufacture of commercial scale batches of API, and a Cortrophin Gel fill/finish contract manufacturer. On October 29, 2021, the U.S. Food and Drug Administration (“FDA”) approved the Company’s Supplemental New Drug Application (“sNDA”) for Cortrophin Gel for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (“MS”) and rheumatoid arthritis (“RA”), in addition to excess urinary protein due to nephrotic syndrome. Cortrophin Gel is an adrenocorticotropic hormone (“ACTH”), also known as purified corticotropin. On January 24, 2022, we announced the commercial launch of Cortrophin Gel in the U.S. as our foundational Rare Disease asset.

In September 2024, we acquired ILUVIEN and YUTIQ (the "Retina Franchise") in connection with the acquisition of Alimera. The acquisition of Alimera is anticipated to strengthen our Rare Disease business and expands our footprint beyond the U.S. with the addition of Alimera's direct marketing operations located in Germany, the United Kingdom, Portugal, and Ireland, as well as its partnerships in Europe, Asia, and the Middle East. We believe that the Retina Franchise is durable with high barriers to genericization and a clear role for patients in need of alternative therapeutic options. ANI sees the potential to unlock significant additional growth for the Retina Franchise through commercial synergies and execution. Importantly, the addition of Alimera expands the reach of the ophthalmology sales team and we believe there will be significant overlap between high potential prescribers of Cortrophin Gel and the Retina Franchise.

We plan to continue to expand our Rare Disease business, through a combination of organic growth and acquisition. While we execute against our strategic initiatives that we believe will result in the long-term, sustainable growth and value to our stockholders, we continue to evaluate potential acquisitions and other strategic transactions of businesses that we believe complement our existing portfolio, infrastructure and capabilities or provide us with the opportunity to expand our existing capabilities. The Brands portion of the segment is comprised of various branded products.

During March 2025, the FDA approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) to include an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye ("NIU-PS") in addition to the then current indication of DME. The Company is currently marketing ILUVIEN for both indications in the U.S. ILUVIEN was already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries. In order to support the transition to ILUVIEN, in July 2024, the Company extended its partnership with Alliance Medical Products, Inc., a subsidiary of Siegfried Holding AG ("Siegfried"), its long-term supplier for ILUVIEN, through 2029, and contracted with Siegfried to upgrade equipment on the existing manufacturing line and significantly expand capacity through the addition of a second manufacturing line. During the second quarter of 2025, we transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN with its combined label of DME and NIU-PS.

Additionally, on February 28, 2025, the FDA approved a prefilled syringe format for Cortrophin Gel. This new presentation became available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options through Cortrophin Gel's established specialty pharmacy network during the second quarter of 2025. The prefilled syringe reduces administration steps for patients using Cortrophin Gel, which remains available in 5 mL and 1 mL vials.

### **Brands**

We have grown our brands portfolio of products through acquisition. We have acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Inderal LA, Inderal XL, InnoPran XL, Inzirqo, Lithobid, Oxistat, Vancocin, and Veregen. We are innovating in our go-to-market strategy through creative partnerships and a sales force for these products.

### ***Strengthening our Generics and Other segment through continued investment in our generic research and development capability and increased focus on niche opportunities***

We have grown our generics business through a combination of market share gains on existing products and new product launches. We have also successfully acquired numerous ANDAs through business and asset acquisitions. Our most recent business acquisition in the Generics and Other segment was the acquisition of Novitium in 2021, which included its portfolio of commercial and pipeline generic products, manufacturing and development facilities and expert workforce. The Novitium acquisition significantly increased our generic pharmaceutical research and development and manufacturing capabilities. We have begun to increase our focus on niche lower competition opportunities such as injectables, Paragraph IV, and competitive generic therapy ("CGT") designation filings.

Additionally, we will continue to seek opportunities to enhance our capabilities through strategic partnerships and acquisitions of assets and businesses.

### **Recent Developments**

#### ***Purchase of SWK Royalty***

Pursuant to a Royalty Purchase Agreement dated as of December 17, 2020, EyePoint Pharmaceuticals US, Inc. (f/k/a pSivida US, Inc. or "EyePoint") sold its right to receive royalty payments on future sales of ILUVIEN to SWK Funding LLC ("SWK") under the existing collaboration agreement entered into in July 2017 between EyePoint and the Company (the "RPA Transaction"). In connection with the RPA Transaction, the Company agreed to pay such royalty payments directly to SWK (see Note 11 "Goodwill and Intangible Assets" to the notes to the condensed consolidated financial statements (unaudited)).

On June 19, 2024, Alimera entered into a letter agreement with SWK, pursuant to which the parties agreed to a lower fixed royalty payment of 3.125% (the “Alternative Royalty”) on combined sales of ILUVIEN and YUTIQ. The letter agreement included a buy-out of the Alternative Royalty at Alimera’s option at any time during the period within six (6) months after a change of control of Alimera, after which SWK would have no further right to receive any payments under the letter agreement or the RPA (the “Buy-Out Option”). On March 17, 2025, the Company exercised the Buy-Out Option and paid SWK \$17.3 million with cash on hand, and as such, no further royalty is due to SWK on net revenues beginning January 1, 2025, forward.

#### ***Acquisition of Alimera Sciences, Inc.***

On September 16, 2024, the Company completed our previously announced merger with Alimera (the “Closing”). At the effective time of the Merger (the “Effective Time”), each share of common stock, par value \$0.01 per share, of Alimera (the “Alimera Common Stock”) outstanding immediately prior to the Effective Time including each Alimera RSA, Alimera PSU, Alimera RSU, and Alimera Warrant (as defined below), but excluding any treasury shares or shares owned by the Company, Merger Subs or any other subsidiary of the Company or Alimera, was canceled and ceased to exist and was converted into the right to receive (i) \$5.50 in cash (“Closing Cash Consideration”), and (ii) one contingent value right (a “CVR”), which represents the right to receive the milestone payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement entered into on September 16, 2024 (clauses (i) and (ii) collectively, the “Merger Consideration”). The Company also repaid \$72.5 million of Alimera debt.

Each CVR entitles the holder to receive milestone payments for 2026 and 2027. The milestone payments for each CVR equals the product (rounded to the nearest 1/100 of \$0.01) of \$0.25 multiplied by a fraction (which is no case will exceed one), and (i) for 2026, equals the amount, if any, by which the 2026 Net Revenue exceeds \$140.0 million, divided by \$10.0 million (subject to adjustment for the exercise price of eligible options), and (ii) for 2027, equals the amount, if any, by which the 2027 Net Revenue exceeds \$160.0 million, divided by \$15.0 million (subject to adjustment for the exercise price of applicable Alimera Options).

In addition to the amounts payable to the holders thereof in connection with the Closing, all of the outstanding awards of restricted stock with respect to shares of Alimera Common Stock (each, an “Alimera RSA”), each Alimera Performance Stock Unit (“Alimera PSU”), each Alimera Restricted Stock Unit (“Alimera RSU”) and each Alimera Warrant that were outstanding immediately prior to the Effective Time were automatically canceled and converted into the right to receive one (1) CVR per share of Alimera Common Stock then underlying the applicable instrument.

Each stock option previously granted by Alimera to purchase Alimera Common Stock (each, an “Alimera Option”) that was outstanding and unexercised as of the Effective Time and which had a per share exercise price that was less than the Closing Cash Consideration was, in addition to the amounts payable to the holders thereof in connection with the Closing, automatically canceled and converted into the right to receive one (1) CVR per share of Alimera Common Stock then underlying such Alimera Option. No other Alimera Options were cancelled and converted into the right to receive a CVR, provided that each Alimera Option with a per share exercise price greater than or equal to the Closing Cash Consideration but less than the Total Consideration (as defined in the Merger Agreement) may receive a payment in connection with the payout of the CVRs (if any). The Company incurred approximately \$0.4 million and \$1.6 million of transaction and integration costs during the three and nine months ended September 30, 2025, related to the Merger Agreement, all of which were expensed. The Company incurred approximately \$13.2 million of transaction and integration costs during the nine months ended September 30, 2024. See Note 3 “Business Combination” to the notes to the condensed consolidated financial statements (unaudited) for further information on the acquisition.

#### ***Capital Structure***

On March 8, 2021, concurrently with the acquisition of Novitium, and as financing for a portion of the acquisition, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the “PIPE Investor”), pursuant to which the PIPE Investor purchased 25,000 shares of Series A Convertible Preferred Stock (the “PIPE Shares”), for a purchase price of \$1,000 per share and an aggregate purchase price of \$25.0 million on November 19, 2021. The PIPE Shares were classified as mezzanine equity because the shares were mandatorily redeemable for cash upon a change in control, an event that was not solely within the Company’s control.

The PIPE Shares accrued dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and participated, on a pro-rata basis, in any dividends that would be declared with respect to the Company’s common stock. The PIPE Shares were convertible into common shares at the conversion price of \$41.4662 (i) beginning two years after their issuance date, at the election of ANI, if the volume-weighted average price of the common stock for any 20 trading days out of 30 consecutive trading days exceeds 170% of the conversion price, or (ii) at any time after issuance, at the election of the PIPE Investor.

On August 14, 2025, the PIPE Investor converted 5,000 PIPE Shares into 120,580 shares of common stock based on the conversion price of \$41.4662 per share. On September 26, 2025, pursuant to the notice dated September 22, 2025, the Company elected mandatory conversion of the remaining 20,000 outstanding PIPE Shares into 482,320 shares of common stock based on the conversion price of \$41.4662 per share, as the conditions for conversion had been satisfied. There were no shares of Series A convertible preferred stock outstanding as of September 30, 2025.

Refer to the Liquidity and Capital Resources below for further discussion of changes to our capital structure during 2024.

### Results of NEW DAY Study

On July 23, 2025, we announced results from the NEW DAY clinical trial of ILUVIEN for use in patients with DME. The results were presented in a paper-on-demand presentation by Michael A. Singer, M.D. for the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. On July 23, 2025, the Company issued a press release describing the results of the NEW DAY clinical trial of ILUVIEN. On the same date, the Company filed a Current Report on Form 8-K that incorporated the press release by reference therein.

### Product Launches

Refer to our website at [www.anipharma.com](http://www.anipharma.com) for information on the products, including indications/treatments.

### Reportable Segments

In connection with the acquisition of Alimera, the Company has assessed its strategic goals and aligned its operational initiatives into two reportable segments, and the discussion of the historical results of operations below has been revised, as applicable, to be consistent with the presentation of the revised reportable segments (see Note 18 "Segment Reporting" to the notes to the condensed consolidated financial statements (unaudited)).

### GENERAL

Impacts to our third quarter 2025 and 2024 results of operations, including to net revenues, operating expenses, interest and other expense, net, and income taxes are described below. The following table summarizes our results of operations for the periods indicated:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Net Revenues	\$ 227,813	\$ 148,332	\$ 636,306	\$ 423,802
Operating Expenses				
Cost of sales (excluding depreciation and amortization)	93,389	63,075	241,041	169,930
Research and development	12,304	10,128	39,403	27,935
Selling, general, and administrative	76,656	79,075	234,955	179,917
Depreciation and amortization	22,632	15,748	68,804	45,131
Contingent consideration fair value adjustment	(14,470)	825	(25,285)	1,274
Loss (gain) on disposal of assets	295	—	295	(5,347)
Intangible asset impairment charge	767	—	767	—
Operating income (loss)	36,240	(20,519)	76,326	4,962
Unrealized gain on investment in equity securities	3,140	1,355	2,551	8,298
Interest expense, net	(4,727)	(2,331)	(15,649)	(11,587)
Other (expense) income, net	(853)	(2,535)	1,084	(2,655)
Loss on extinguishment of debt	—	(7,468)	—	(7,468)
Income (Loss) Before Income Tax Expense (Benefit)	33,800	(31,498)	64,312	(8,450)
Income tax expense (benefit)	7,183	(7,332)	13,465	(204)
Net Income (Loss)	\$ 26,617	\$ (24,166)	\$ 50,847	\$ (8,246)

The following table sets forth, for all periods indicated, items in our unaudited condensed consolidated statements of operations as a percentage of net revenues:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Net Revenues	100 %	100 %	100 %	100 %
Operating Expenses				
Cost of sales (excluding depreciation and amortization)	41.0 %	42.5 %	37.9 %	40.1 %
Research and development	5.4 %	6.8 %	6.2 %	6.6 %
Selling, general, and administrative	33.6 %	53.3 %	36.9 %	42.5 %
Depreciation and amortization	9.9 %	10.6 %	10.8 %	10.6 %
Contingent consideration fair value adjustment	(6.4)%	0.6 %	(4.0)%	0.3 %
Loss (gain) on disposal of assets	0.1 %	— %	— %	(1.3)%
Intangible asset impairment charge	0.3 %	— %	0.1 %	— %
Operating income (loss)	16.1 %	(13.8)%	12.1 %	1.2 %
Unrealized gain on investment in equity securities	1.4 %	0.9 %	0.4 %	2.0 %
Interest expense, net	(2.1)%	(1.6)%	(2.5)%	(2.7)%
Other (expense) income, net	(0.4)%	(1.7)%	0.2 %	(0.6)%
Loss on extinguishment of debt	— %	(5.0)%	— %	(1.8)%
Income (Loss) Before Income Tax Expense (Benefit)	15.0 %	(21.2)%	10.2 %	(1.9)%
Income tax expense (benefit)	3.2 %	(4.9)%	2.1 %	— %
Net Income (Loss)	11.8 %	(16.3)%	8.1 %	(1.9)%

## RESULTS OF OPERATIONS

### RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

#### Net Revenues

(in thousands)	Three Months Ended September 30,		Change	% Change
	2025	2024		
<b>Rare Disease and Brands</b>				
Cortrophin Gel	\$ 101,850	\$ 52,555	\$ 49,295	93.8 %
ILUVIEN and YUTIQ	16,600	3,871	12,729	N/M
<b>Rare Disease total net revenues</b>	<b>\$ 118,450</b>	<b>\$ 56,426</b>	<b>\$ 62,024</b>	<b>109.9 %</b>
Brands	10,675	9,195	1,480	16.1 %
<b>Rare Disease and Brands total net revenues</b>	<b>\$ 129,125</b>	<b>\$ 65,621</b>	<b>\$ 63,504</b>	<b>96.8 %</b>
<b>Generics and Other</b>				
Generic pharmaceutical products	94,375	78,223	16,152	20.6 %
Royalties and other pharmaceutical services	4,313	4,488	(175)	(3.9)%
<b>Generics and Other total net revenues</b>	<b>\$ 98,688</b>	<b>\$ 82,711</b>	<b>\$ 15,977</b>	<b>19.3 %</b>
<b>Total net revenues</b>	<b>\$ 227,813</b>	<b>\$ 148,332</b>	<b>\$ 79,481</b>	<b>53.6 %</b>

"N/M" - not meaningful percentage due to the acquisition of ILUVIEN and YUTIQ on September 16, 2024.

We derive substantially all of our revenues from sales of rare disease, brands portfolio of pharmaceutical products, generics, and other sources of revenue such as royalties on net sales of certain products, and other pharmaceutical services. Essentially all of our generic products face competition from other generic products, as do many of our brands products, and we expect them to continue to face competition from generic products in the future. The primary means of competition among generic manufacturers are pricing, contract terms, service levels, and reliability. Increased competition generally results in decreased average selling prices of generic and brands products over time. In addition, due to strategic partnerships between wholesalers and pharmacy chains, we have experienced, and expect to continue to experience, increases in net sales to the wholesalers, with corresponding decreases in net sales to the pharmacy chains.

Net revenues for the three months ended September 30, 2025 were \$227.8 million compared to \$148.3 million for the same period in 2024, an increase of 53.6%, primarily as a result of the following:

- Net revenues from Rare Disease and Brands, includes rare disease and brands portfolio of pharmaceutical products were \$129.1 million during the three months ended September 30, 2025, an increase of \$63.5 million, compared to \$65.6 million, for the same period in 2024.
  - Net revenues for Rare Disease pharmaceutical products were \$118.5 million during the three months ended September 30, 2025, an increase of \$62.0 million from \$56.4 million for the same period in 2024. This increase was driven by increased volume of Cortrophin Gel from overall ACTH market growth and share growth, and a full quarter of sales from ILUVIEN, as a result of the acquisition of Alimera on September 16, 2024.
  - Net revenues for our Brands portfolio of pharmaceutical products were \$10.7 million during the three months ended September 30, 2025, an increase of \$1.5 million compared to \$9.2 million for the same period in 2024, driven by a net increase in demand for certain products during the third quarter.

- Net revenues for Generic and Other pharmaceutical products were \$98.7 million during the three months ended September 30, 2025, an increase of 19.3% compared to \$82.7 million for the same period in 2024, primarily a result of the following:
  - Generic pharmaceutical products net revenues were \$94.4 million during the three months ended September 30, 2025, an increase of \$16.2 million over the prior year. This increase was driven by a partnered product launched in the third quarter, increased volumes from the benefit of new product launches during 2025, along with annualization of new product launches that occurred during 2024. These gains were somewhat tempered by net decreases in products that were launched prior to 2024. The Company launched a total of 17 new products in 2024. From a product perspective, the increase was principally driven by revenues from year over year increases in products such as Estradiol, Ketoconazole, Nitazoxanide, Promethazine HCL and Dextromehorphan HBM, Prucalopride, and the partnered product launched in the third quarter, among others. We currently anticipate that revenues from Generic pharmaceutical products will be lower in the fourth quarter compared to that in the third quarter of 2025 due to expected competition on certain products.
  - Net revenues from royalties and other pharmaceuticals was down modestly for the three months ended September 30, 2025, compared to the same time in the prior year.

#### Cost of Sales (Excluding Depreciation and Amortization)

(in thousands)	Three Months Ended September 30,		Change	% Change
	2025	2024		
Cost of sales (excluding depreciation and amortization)	\$ 93,389	\$ 63,075	\$ 30,314	48.1 %

Cost of sales consists of direct labor, including manufacturing and packaging, active and inactive pharmaceutical ingredients, freight costs, packaging components, royalties payable related to profit-sharing arrangements. Cost of sales does not include depreciation and amortization expense, which is reported as a separate component of operating expenses on our unaudited condensed consolidated statements of operations.

For the three months ended September 30, 2025, cost of sales increased to \$93.4 million from \$63.1 million for the same period in 2024, an increase of \$30.3 million, or 48.1%. The increase is primarily due to significant net growth in sales volumes of pharmaceutical products and significant growth of royalty bearing products, including Cortrophin Gel, and other products in our portfolio.

Cost of sales, as a percentage of net revenues, decreased to 41.0% from 42.5% for the three months ended September 30, 2025, compared to the same period in 2024, primarily due to the non-recurrence of \$3.2 million of the inventory step-up related to the acquisition of Alimera.

During the three months ended September 30, 2025, approximately 21% of our raw material inventory purchases were from one domestic supplier. During the three months ended September 30, 2024, no single vendor represented more than 10% of our raw material inventory purchases.

## Other Operating Expenses, net

(in thousands)	Three Months Ended September 30,		Change	% Change
	2025	2024		
Research and development	\$ 12,304	\$ 10,128	\$ 2,176	21.5 %
Selling, general, and administrative	76,656	79,075	(2,419)	(3.1)%
Depreciation and amortization	22,632	15,748	6,884	43.7 %
Contingent consideration fair value adjustment	(14,470)	825	(15,295)	(1853.9)%
Loss on disposal of assets	295	—	295	100.0 %
Intangible asset impairment charge	767	—	767	100.0 %
Total other operating expenses, net	\$ 98,184	\$ 105,776	\$ (7,592)	(7.2)%

For the three months ended September 30, 2025, total other operating expenses, net decreased to \$98.2 million from \$105.8 million for the same period in 2024, a decrease of \$7.6 million, or 7.2%, primarily as a result of the following factors:

- Research and development expenses during the three months ended September 30, 2025 increased from \$10.1 million to \$12.3 million, an increase of 21.5% or \$2.2 million, primarily due to a higher level of activity and timing associated with ongoing and new projects to support future growth of Rare Disease and Generics in the three months ended September 30, 2025.
- Selling, general, and administrative expenses decreased from \$79.1 million to \$76.7 million, a slight decrease of approximately \$2.4 million, primarily driven by the decrease of approximately \$9.3 million in transaction and integration costs and \$14.5 of severance and equity payments related to the Alimera acquisition, offset by increased costs associated with Rare Disease sales and marketing efforts of approximately \$10 million and increase in legal costs of approximately \$4 million, and other expenses related to the growth of our business.
- Depreciation and amortization expense was \$22.6 million for the three months ended September 30, 2025, compared to \$15.7 million for the same period in 2024 an increase of approximately \$6.9 million, primarily related to the full quarter of amortization expense of ILUVIEN, which amounted to approximately \$8.2 million for the current quarter, compared to \$1.4 million of amortization expense for only a portion of the quarter in the prior year. These assets were acquired on September 16, 2024 from Alimera.
- We recognized a gain of \$14.5 million for the three months ended September 30, 2025 for the contingent consideration fair value adjustments, which consisted of three components: the gain in fair value related to (1) the accrued Alimera licensor payments, (2) the Novitium contingent consideration, and (3) the contingent value rights related to the acquisition of Alimera. We recorded a gain in fair value related to the adjustment of future cash flows and a related decrease in the expected future payments of approximately \$7.4 million related to the accrued licensor fees, a gain in fair value of approximately \$4.6 million related related to Novitium contingent consideration, and a gain of approximately \$2.5 million related to the contingent value rights.
- We recognized a loss related to the disposal of certain manufacturing equipment of approximately \$0.3 million during the three months ended September 30, 2025. There was no comparable disposals during the three months ended September 30, 2024.
- We recognized an impairment charge related to a definite-lived intangible asset of approximately \$0.8 million during the three months ended September 30, 2025. There was no comparable intangible asset impairment charge in the three months ended September 30, 2024.

## Other Expense, net

(in thousands)	Three Months Ended September 30,		Change	% Change
	2025	2024		
Unrealized gain on investment in equity securities	\$ 3,140	\$ 1,355	\$ 1,785	131.7 %
Interest expense, net	(4,727)	(2,331)	(2,396)	102.8 %
Other expense, net	(853)	(2,535)	1,682	(66.4)%
Loss on extinguishment of debt	—	(7,468)	7,468	(100.0)%
Total other expense, net	\$ (2,440)	\$ (10,979)	\$ 8,539	(77.8)%

For the three months ended September 30, 2025, we recognized total other expense, net of \$2.4 million as compared to \$11.0 million for the same period in 2024.

- We recorded an unrealized gain on our investment in equity securities of approximately \$3.1 million for the three months ended September 30, 2025, compared to an unrealized gain in the same period in 2024, which is based on the mark to market to fair value of equity securities held in CG Oncology as of the balance sheet date, and an increase of the trading price of the securities.
- Interest expense, net for the three months ended September 30, 2025 consists primarily of coupon interest expense on borrowings under our outstanding debt and amortization of deferred financings costs on these debt instruments, and interest income earned on our bank balances. The increase in interest expense, net, of \$2.4 million is primarily attributable to an increase in interest expense related to our New Credit Agreement of \$0.6 million and Convertible Senior Notes of \$0.8 million, an increase in amortization of deferred financing fees of \$0.2 million, and a decrease in interest earned on bank balances of approximately \$0.4 million during the three months ended September 30, 2025 as compared to prior year.
- Other expense, net, for the three months ended September 30, 2025 consists primarily of foreign exchange gains and losses related to our international entities.
- In the prior year period, we recorded a loss on debt extinguishment of approximately \$7.5 million, comprised of the write-off unamortized deferred financing fees related to the Credit Facility. On August 13, 2024, the Company entered into the 2.25% Convertible Senior Notes due 2029 (as described in Note 7 “2.25% Convertible Senior Notes” to the Notes to Condensed Consolidated Financial Statements). The proceeds of the 2.25% Convertible Senior Notes were used to repay the Truist Credit Facility in its entirety, approximately \$294.0 million, comprised of \$292.5 million of unpaid principal, \$1.2 million in accrued and unpaid interest, and \$0.3 million of legal fees. There was no comparable transaction in the three months ended September 30, 2025.

#### Income Tax Expense (Benefit)

(in thousands)	Three Months Ended September 30,		Change	% Change
	2025	2024		
Income tax expense (benefit)	\$ 7,183	\$ (7,332)	\$ 14,515	(198.0)%

Income tax expense (benefit) consists of current and deferred components, which include changes in our deferred tax assets, our deferred tax liabilities, and our valuation allowance.

For the three months ended September 30, 2025, we recognized an income tax expense of approximately \$7.2 million, an effective tax rate of 21.3% of pre-tax income reported in the period, as well as the net effect of certain discrete items for the three months ended September 30, 2025 which impact our income tax expense in the period in which they occur. The effective tax rate differed from the federal statutory rate of 21% primarily due to excess tax benefits recognized upon settlement of stock-based compensation and non-taxable adjustments to the fair value of certain contingent liabilities related to the acquisition of Alimera.

For the three months ended September 30, 2024, we recognized an income tax benefit of \$7.3 million. The Company's effective tax rate was 23.3% after discrete items for the three months ended September 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, and non-deductible expenses related to the pending business combination which were treated as a discrete item during the quarter which affects the estimated tax rate.

**RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024**

**Net Revenues**

(in thousands)	Nine Months Ended September 30,		Change	% Change
	2025	2024		
<b>Rare Disease and Brands</b>				
Cortrophin Gel	\$ 236,347	\$ 138,685	\$ 97,662	70.4 %
ILUVIEN and YUTIQ	55,025	3,871	51,154	N/M
<b>Rare Disease total net revenues</b>	<b>\$ 291,372</b>	<b>\$ 142,556</b>	<b>\$ 148,816</b>	<b>104.4 %</b>
Brands	48,993	44,900	4,093	9.1 %
<b>Rare Disease and brands total net revenues</b>	<b>\$ 340,365</b>	<b>\$ 187,456</b>	<b>\$ 152,909</b>	<b>81.6 %</b>
<b>Generics and Other</b>				
Generic pharmaceutical products	283,350	222,404	60,946	27.4 %
Royalties and other pharmaceutical services	12,591	13,942	(1,351)	(9.7)%
<b>Generics and Other total net revenues</b>	<b>\$ 295,941</b>	<b>\$ 236,346</b>	<b>\$ 59,595</b>	<b>25.2 %</b>
<b>Total net revenue</b>	<b>\$ 636,306</b>	<b>\$ 423,802</b>	<b>\$ 212,504</b>	<b>50.1 %</b>

"N/M" - not meaningful percentage due to the acquisition of ILUVIEN and YUTIQ on September 16, 2024.

Net revenues for the nine months ended September 30, 2025 were \$636.3 million compared to \$423.8 million for the same period in 2024, an increase of 50.1%, primarily as a result of the following:

- Net revenues from Rare Disease and Brands, includes rare disease and brands portfolio of pharmaceutical products were \$340.4 million during the nine months ended September 30, 2025, an increase of \$152.9 million, compared to \$187.5 million, for the same period in 2024.
  - Net revenues for Rare Disease pharmaceutical products were \$291.4 million during the nine months ended September 30, 2025, an increase of \$148.8 million from \$142.6 million for the same period in 2024. This increase was driven by increased volume of Cortrophin Gel from overall ACTH market growth and share growth and three full quarters of sales from ILUVIEN and YUTIQ, as a result of the acquisition of Alimera on September 16, 2024.
  - Net revenues for Brands portfolio of pharmaceutical products were \$49.0 million during the nine months ended September 30, 2025, an increase of \$4.1 million compared to \$44.9 million for the same period in 2024, driven by a net increase in demand for certain products, and we anticipate a return to a more normalized level during Q4 of 2025.
- Net revenues for Generic and Other pharmaceutical products were \$295.9 million during the nine months ended September 30, 2025, an increase of 25.2% compared to \$236.3 million for the same period in 2024, primarily a result of the following:
  - Generic pharmaceutical products net revenues were \$283.4 million during the nine months ended September 30, 2025, an increase of \$60.9 million over the prior year. This increase was driven by the late 2024 launch of Prucalopride Tablets, which was launched with CGT designation and corresponding 180 day exclusivity that expired in late June, increased volumes from the benefit of new product launches during the first three quarters of 2025, inclusive of a partnered generic product launched in Q3 2025, along with annualization of new product launches that occurred during 2024. The Company launched a total of 17 new products in 2024. From a product perspective, the increase was principally driven by revenues from year over year increases in products such as Candesartan, Estradiol, Ketoconazole, Kionex, L-Glutamine, Nitazoxanide, Promethazine HCL and Dextromehorphan HBM, Prucalopride, among others. We currently anticipate that revenues from Generic pharmaceutical products will be lower in the fourth quarter compared to that in the third quarter of 2025 due to expected competition on certain products.

- Net revenues from royalties and other pharmaceuticals was down modestly for the nine months ended September 30, 2025, compared to the same period in the prior year.

#### Cost of Sales (Excluding Depreciation and Amortization)

(in thousands)	Nine Months Ended September 30,		Change	% Change
	2025	2024		
Cost of sales (excluding depreciation and amortization)	\$ 241,041	\$ 169,930	\$ 71,111	41.8 %

For the nine months ended September 30, 2025, cost of sales increased to \$241.0 million from \$169.9 million for the same period in 2024, an increase of \$71.1 million, or 41.8%. The increase is primarily due to significant net growth in sales volumes of pharmaceutical products and significant growth of royalty bearing products, including Cortrophin Gel and other products in our portfolio.

Cost of sales, as a percentage of net revenues, decreased to 37.9% from 40.1% for the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to a shift in product mix year over year.

During the nine months ended September 30, 2025, approximately 22% of our raw material inventory purchases were from one domestic supplier. During the nine months ended September 30, 2024, approximately 17% of our raw material inventory purchases were from one domestic supplier.

#### Other Operating Expenses, net

(in thousands)	Nine Months Ended September 30,		Change	% Change
	2025	2024		
Research and development	\$ 39,403	\$ 27,935	\$ 11,468	41.1 %
Selling, general, and administrative	234,955	179,917	55,038	30.6 %
Depreciation and amortization	68,804	45,131	23,673	52.5 %
Contingent consideration fair value adjustment	(25,285)	1,274	(26,559)	(2084.7)%
Loss (gain) on disposal of assets	295	(5,347)	5,642	(105.5)%
Intangible asset impairment charge	767	—	767	100.0 %
Total other operating expenses, net	\$ 318,939	\$ 248,910	\$ 70,029	28.1 %

For the nine months ended September 30, 2025, total other operating expenses, net increased to \$318.9 million from \$248.9 million for the same period in 2024, an increase of \$70.0 million, or 28.1%, primarily as a result of the following factors:

- Research and development expenses increased to \$39.4 million from \$27.9 million, an increase of \$11.5 million or 41.1%, primarily due to a higher level and timing of activity associated with ongoing and new projects to support future growth of Rare Disease and Generics in the nine months ended September 30, 2025.
- Selling, general, and administrative expenses increased from \$179.9 million to \$235.0 million, an increase of \$55.0 million, or 30.6%, due to increased employment related costs, investment in Rare Disease sales and marketing infrastructure including our new, larger ophthalmology sales and marketing team and activities, legal expenses, and an overall increase in activities to support the growth of our business in the current year; tempered by a decrease of approximately \$11.0 million related to transaction and integration costs, and \$14.4 million related to severance and equity payments incurred during the nine months ended September 30, 2024, which did not recur in the current year.
- Depreciation and amortization expense was \$68.8 million for the nine months ended September 30, 2025, compared to \$45.1 million for the same period in 2024, an increase of approximately \$23.7 million, primarily related to the amortization expense of the acquired intangible assets, ILUVIEN and YUTIQ, which amounted to approximately \$24.6 million for the nine months ended September 30, 2025. These assets were acquired on September 16, 2024 from Alimera.

- We recognized a gain of \$25.3 million for the nine months ended September 30, 2025 for the contingent consideration fair value adjustments, which consisted of three components: the gain in fair value related to (1) the accrued Alimera licensor payments; (2) the Alimera contingent value rights; and (3) the Novitium contingent consideration. We recorded a gain in fair value related to the adjustment of future cash flows and a related decrease in the expected future payments of approximately \$16.9 million related to the accrued licensor fees, a \$5.5 million gain related to the contingent value rights, and a gain of \$2.9 million related to the Novitium contingent consideration.
- We recognized a loss related to the disposal of certain manufacturing equipment of approximately \$0.3 million during the nine months ended September 30, 2025, and a gain related to the sale of the former Oakville, Ontario manufacturing site of approximately \$5.3 million during the nine months ended September 30, 2024.
- We recognized an impairment charge related to one definite-lived intangible asset of approximately \$0.8 million during the nine months ended September 30, 2025. There was no comparable intangible asset impairment charge in the nine months ended September 30, 2024.

#### Other Expense, net

(in thousands)	Nine Months Ended September 30,		Change	% Change
	2025	2024		
Unrealized gain on investment in equity securities	\$ 2,551	\$ 8,298	\$ (5,747)	(69.3)%
Interest expense, net	(15,649)	(11,587)	(4,062)	35.1 %
Other income (expense), net	1,084	(2,655)	3,739	(140.8)%
Loss on extinguishment of debt	—	(7,468)	7,468	(100.0)%
Total other expense, net	\$ (12,014)	\$ (13,412)	\$ 1,398	(10.4)%

For the nine months ended September 30, 2025, we recognized total other expense, net of \$12.0 million as compared to total other expense of \$13.4 million for the same period in 2024.

- We recorded an unrealized gain on our investment in equity securities of approximately \$2.6 million for the nine months ended September 30, 2025, compared to an unrealized gain in the same period in 2024, which is based on the mark to market to fair value of equity securities held in CG Oncology as of the balance sheet date.
- Interest expense, net for the nine months ended September 30, 2025 consists primarily of coupon interest expense on borrowings under our outstanding debt and amortization of deferred financings costs on these debt instruments, interest income earned on our bank balances, and interest earned on our interest rate swap. The increase in interest expense, net, of \$4.1 million is primarily attributable to favorable decrease in interest expense on our New Credit Agreement of \$5.2 million as compared to our previous Credit Agreement, offset by a decrease in bank interest income of approximately \$4.2 million related to bank balances and interest income from interest rate swaps, nine months of interest expense related to our Convertible Senior Notes, an increase of approximately \$4.3 million over the same period in the prior year, and increase in amortization of deferred financing costs of approximately \$0.7 million.
- Other income (expense), net, for the nine months ended September 30, 2025 consists primarily of foreign exchange gains and losses related to our international entities.
- We recorded a loss on debt extinguishment of approximately \$7.5 million, comprised of the write-off unamortized deferred financing fees related to the Credit Facility. On August 13, 2024, the Company entered into the 2.25% Convertible Senior Notes due 2029 (as described in Note 7 “2.25% Convertible Senior Notes” to the Notes to Condensed Consolidated Financial Statements). The proceeds of the 2.25% Convertible Senior Notes were used to repay the infrastructure Credit Facility in its entirety, approximately \$294.0 million, comprised of \$292.5 million of unpaid principal, \$1.2 million in accrued and unpaid interest, and \$0.3 million of legal fees. There was no comparable transaction in the nine months ended September 30, 2025.

## Income Tax Expense (Benefit)

(in thousands)	Nine Months Ended September 30,		Change	% Change
	2025	2024		
Income tax expense (benefit)	\$ 13,465	\$ (204)	\$ 13,669	(6700.5)%

For the nine months ended September 30, 2025, we recognized an income tax expense of approximately \$13.5 million, an effective tax rate of 20.9% of pre-tax income reported in the period, as well as the net effect of certain discrete items for the nine months ended September 30, 2025 which impact our income tax expense in the period in which they occur. The effective tax rate differed from the federal statutory rate of 21% primarily due to excess tax benefits recognized upon settlement of stock-based compensation, favorable return to provision adjustments attributable to certain foreign tax returns filed during the period, and non-taxable adjustments to the fair value of certain contingent liabilities related to the acquisition of Alimera.

For the nine months ended September 30, 2024, the Company recognized an income tax benefit of \$0.2 million. The Company's effective tax rate was 2.4% after discrete items for the nine months ended September 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, tax on the sale of the Oakville, Ontario manufacturing site, and recording of a withholding tax liability on the proceeds of the sale, and non-deductible expenses related to the 2024 business combination.

## LIQUIDITY AND CAPITAL RESOURCES

### Term Loan A

On August 13, 2024, the Company, as lead borrower, entered into a delayed-draw credit agreement (the "New Credit Agreement") with JPMorgan Chase Bank, N.A., and other financial institutions (together, the "Lenders"), which provides for aggregate principal commitments consisting of (i) a senior secured term loan facility in an aggregate principal amount of \$325.0 million (the "Term Loan A" or "TLA"), and (ii) a senior secured revolving credit facility in an aggregate commitment amount of \$75.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the "TLA Revolver" and together with the TLA, the "New Credit Facility").

On September 16, 2024 (the "Closing Date") the Company drew the full \$325.0 million of Term Loan A principal on September 16, 2024, with proceeds used to finance the acquisition of Alimera, including fees, costs and expenses incurred in connection with the transaction. As of September 30, 2025, \$74.9 million is available for borrowing under the TLA Revolver, subject to certain conditions. The TLA and the TLA Revolver mature on September 16, 2029. The New Credit Facility contains certain contingent acceleration clauses, none of which have been triggered as of September 30, 2025. The cash interest rate and effective rate under the Term Loan A was approximately 6.76% and 7.12%, respectively, at September 30, 2025.

We are required to make quarterly principal payments, beginning on December 31, 2024, in the amount of (i) 0.625% of the original principal amount of the Term Loan A on each quarterly payment date on or prior to the one year anniversary of the Closing Date, (ii) 1.25% of the original principal amount of the Term Loan A on each quarterly payment date following the one year anniversary of the Closing Date and 1.875% of the original principal amount of the Term Loan A on each quarterly payment date following the three year anniversary of the Closing Date and with the remaining unpaid principal amount due on the maturity date of the Term Loan A. A commitment fee accrues on the unutilized commitments under the TLA Revolver and, from and after the date that is two months after the closing date of the New Credit Agreement, the TLA at a per annum rate equal between 0.25% and 0.40% depending on the Company's first lien net leverage ratio.

The New Credit Agreement also contains certain customary covenants including but not limited to restrictions on the amount of debt the Company and its restricted subsidiaries may incur and payments the Company and its restricted subsidiaries may make, and events of default, as well as, in the event of an occurrence of an event of default, customary remedies for the Lenders, including the acceleration of any amounts outstanding under the New Credit Agreement. The New Credit Facility is secured by a lien on substantially all of the Company's and its principal domestic subsidiary's assets and any future domestic subsidiary guarantors' assets.

## 2.25% Convertible Senior Notes Due 2029

On August 7, 2024, the Company entered into a purchase agreement (the “Purchase Agreement”) with the initial purchasers (the “Initial Purchasers”) relating to the issuance of the \$275.0 million aggregate principal amount of the Company's Convertible Senior Notes due 2029 (the “Notes”). Pursuant to the terms of the Purchase Agreement, the Company granted the Initial Purchasers an option to purchase up to an additional \$41.3 million aggregate principal amount of Notes (the “Option”) for settlement at any time during the thirteen days beginning on, and including, August 7, 2024, which Option was exercised in full on August 8, 2024.

On August 13, 2024 (the “Closing Date” or “Issue Date”), the Company completed an offering of \$316.3 million aggregate principal amount of Notes. The Notes were issued pursuant to an indenture (the “Indenture”) dated as of August 13, 2024 between the Company and U.S. Bank Trust Company, National Association (“Trustee”). The Notes are due September 1, 2029, unless earlier repurchased, redeemed, or converted. The Notes will accrue interest at a rate of 2.25% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2025. After deducting the initial purchasers’ discounts and commissions of approximately \$9.5 million, but before deducting the Company’s offering expenses, the net proceeds to the Company from the offering of the Notes was approximately \$306.8 million. After payment of the cost of entering into the Capped Call Transactions (as defined below), the Company used the remainder of the net proceeds from the Notes offering, together with cash on hand, to repay the Company’s existing senior secured credit agreement, dated as of November 19, 2021, by and among the Company, certain of the Company’s subsidiaries, as guarantors, Truist Bank, as administrative agent and other parties thereto, as amended, in the amount of approximately \$294.0 million, comprised of \$292.5 million of unpaid principal, \$1.2 million in accrued and unpaid interest, and \$0.3 million of legal fees.

In connection with the issuance of the Notes, the Company recorded a loss on debt extinguishment in the unaudited consolidated statement of operations for the three months ended September 30, 2024, amounting to approximately \$7.5 million, comprised of the write-off unamortized deferred financing fees.

The Notes are the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.

Prior to the close of business on the business day immediately preceding June 1, 2029, holders of the Notes will have the right to convert their Notes only upon the occurrence of certain events as set forth in the Indenture. All or any portion of the Notes may be converted prior to June 1, 2029 at the holders’ option upon the occurrence of any of the following: (i) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on September 30, 2024, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price of the Notes for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (ii) during the five consecutive business days immediately after any ten consecutive trading day period (such ten consecutive trading day period, the “measurement period”) in which the trading price per \$1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock on such trading day and the conversion rate of the Notes on such trading day; (iii) upon the occurrence of certain corporate events or distributions on the Company’s common stock, as described in the Indenture; or (iv) if the Company calls such Notes for redemption.

On or after June 1, 2029 until the close of business on the second scheduled trading day immediately before the maturity date of the Notes, holders may convert all or any portion of their Notes at any time at their election. The initial conversion rate for the Notes is 13.4929 shares of the Company’s common stock per \$1,000 principal amount of Notes, which represents an initial conversion price of approximately \$74.11 per share of the Company’s common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for holders that convert their Notes in connection with such Make-Whole Fundamental Change, as described in the Indenture.

Upon conversion of the Notes, the Company will pay cash up to the aggregate principal amount of the Notes to be converted and pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation.

## Capped Call Transactions

In connection with the offering of Notes, on August 7, 2024 and August 8, 2024, the Company entered into capped call transactions with certain financial institutions (“Capped Calls”). The Capped Calls each have an initial strike price of \$114.02, which represents a premium of 100% over the last reported sale price of the Company’s common stock on August 7, 2024. The Company used approximately \$40.6 million of the net proceeds from the offering of the Notes to pay premiums on the Capped Calls.

The Capped Calls are expected to generally to reduce potential dilution to the Company’s common stock upon any conversion of the Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes, as the case may be, with such reductions and/or offset subject to a cap, based on the cap price of the Capped Calls. The Capped Calls cover, subject to anti-dilution adjustments, approximately 4.3 million shares of the Company's common stock.

The Capped Calls will expire upon the maturity of the Notes. The Capped Calls are separate transactions entered into by the Company with the financial institution counterparties thereto, the Capped Calls are not part of the terms of the Notes and the Capped Calls do not change the holders’ rights under the Notes. The Capped Calls do not meet the criteria for separate accounting as a derivative as they meet the criteria for equity classification, and the capped call transaction premiums are recorded as a reduction to Additional Paid-In Capital within Shareholders’ Equity, net of deferred income taxes.

## Accrued Licensor Payments

On May 17, 2023, Alimera entered into a product rights agreement with EyePoint which granted Alimera an exclusive and sublicensable right and license under EyePoint’s and its affiliates’ interest in certain of EyePoint’s and its affiliates’ intellectual property to develop, manufacture, sell, commercialize and otherwise exploit certain products, including YUTIQ, for the treatment and prevention of uveitis in the entire world, except Europe, the Middle East and Africa, where the Company already has such rights pursuant to the New Collaboration Agreement, and except for China, Hong Kong, Macau, Taiwan, Brunei, Burma (Myanmar), Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, South Korea, Thailand and Vietnam, where Ocumension holds a license from EyePoint. Pursuant to the agreement, Alimera paid EyePoint an upfront payment of \$75.0 million and has also made four quarterly guaranteed payments to EyePoint totaling \$7.5 million during the year ended December 31, 2024.

The Company will also pay royalties to EyePoint from 2025 to 2028 at 30% of annual U.S. net sales of certain products (including YUTIQ and ILUVIEN) in excess of certain thresholds, beginning at \$70.0 million in 2025, increasing annually thereafter. Upon making the quarterly payments in the aggregate amount of \$7.5 million in 2024, the licenses and rights granted to the Company will automatically become perpetual and irrevocable.

We believe that our financial resources, consisting of current working capital, anticipated future operating revenue and corresponding collections from customers, our New Credit Facility, under which \$74.9 million remains available for borrowing as of September 30, 2025, and the completed offering of \$316.3 million of 2.25% Convertible Senior Notes, will be sufficient to enable us to meet our working capital requirements and debt obligations for at least the next 12 months from the date of filing of this report, and for the foreseeable future thereafter.

## Cash Flows

The following table summarizes the net cash and cash equivalents (used in) provided by operating activities, investing activities, and financing activities for the periods indicated:

(in thousands)	Nine Months Ended September 30,	
	2025	2024
Operating Activities	\$ 154,858	\$ 48,157
Investing Activities	\$ (32,918)	\$ (394,038)
Financing Activities	\$ (5,308)	\$ 269,852

## Net Cash Provided by Operations

Net cash provided by operating activities was \$154.9 million for the nine months ended September 30, 2025, compared to net cash provided by operating activities of \$48.2 million during the same period in 2024, an increase of \$106.7 million. The increase in cash provided by operating activities primarily resulted from our net income of \$50.8 million adjusted for non-cash items, and an increase in our working capital accounts driven by the growth of our business.

### ***Net Cash Used in Investing Activities***

Net cash used in investing activities for the nine months ended September 30, 2025 was \$32.9 million, principally due to the payment for the exercise of the Buy-Out Option and purchase of other intangible assets of approximately \$20.3 million and capital expenditures of approximately \$12.6 million. Net cash used in investing activities for the nine months ended September 30, 2024 was \$394.0 million, principally due to the acquisition of Alimera of approximately \$393.1 million.

### ***Net Cash (Used in) Provided by Financing Activities***

Net cash used in financing activities for the nine months ended September 30, 2025 was \$5.3 million, principally resulting from \$11.6 million of treasury stock purchases for restricted stock vests, principal payments on our New Credit Facility of \$6.1 million, offset by proceeds received from stock option exercises and ESPP purchases of approximately \$13.6 million. Net cash provided by financing activities for the nine months ended September 30, 2024 was \$269.9 million, principally resulting from proceeds from the New Credit Facility of \$325.0 million, proceeds from the offering of the Convertible Senior Notes of \$316.3 million, offset by the repayment of the Truist Credit Facility of \$292.5 million, purchase of the capped calls of \$40.6 million, payments of debt issuance costs related to the Convertible Senior Notes and New Credit Facility of \$15.4 million, \$12.5 million paid to the Company Members of Novitium, and \$10.6 million of treasury stock purchase, and other items.

### **CRITICAL ACCOUNTING ESTIMATES**

Except for updates to accounting policies as a result of the acquisition of Alimera, as described in Note 1, "Business, Presentation, and Recent Accounting Pronouncements" of the condensed consolidated financial statements (unaudited) included in Part I, Item 1 of this Quarterly Report on Form 10-Q to the accompanying consolidated financial statements, our critical accounting policies and estimates have not changed since December 31, 2024. Our critical accounting estimates were included in Part II, Item 8. Consolidated Financial Statements, Note 1, "Description of Business and Summary of Significant Accounting Policies" in our 2024 Form 10-K.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Market risks include interest rate risk, equity risk, foreign currency exchange rate risk, commodity price risk, and other relevant market rate or price risks. Of these risks, interest rate risk, equity risk, and foreign currency exchange rate risk could have a significant impact on our results of operations. There have been no material changes in our exposure to market risks since the end of the most recent fiscal year as reported in our 2024 Form 10-K.

### **Item 4. Controls and Procedures**

#### ***Evaluation of Disclosure Controls and Procedures***

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management has carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of September 30, 2025. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

#### ***Changes in Internal Control over Financial Reporting***

There were no changes in our internal control over financial reporting, during the quarter ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Part II — OTHER INFORMATION

### Item 1. Legal Proceedings

Please refer to Note 15 "Commitments and Contingencies" in the condensed consolidated financial statements (unaudited) included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.

### Item 1A. Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, please carefully consider the factors described under the heading "Risk Factors" in our 2024 Form 10-K in Part I, Item 1A. The risks described are not the only risks facing us. Additional risks and uncertainties not currently known to us, or that our management currently deems to be immaterial, also may adversely affect our business, financial condition, and/or operating results.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

#### Sales of Unregistered Securities

None.

#### Issuer Purchases of Equity Securities

There were no repurchases of equity securities pursuant to a repurchase plan or program during the three months ended September 30, 2025.

Period	Total Number of Shares Purchased <sup>(1)</sup>	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or approximate dollar value) of Shares that may yet be Purchased Under the Plans or Programs
July 1 - July 31, 2025	2,071	\$ 66.30	—	\$ —
August 1 - August 31, 2025	3,929	\$ 87.47	—	\$ —
September 1 - September 30, 2025	5,987	\$ 94.06	—	\$ —
Total	11,987	\$ 87.10	—	—

<sup>(1)</sup> Shares purchased during the period were transferred to the Company from employees in satisfaction of minimum tax withholding obligations associated with the vesting of restricted stock awards during the period.

### Item 3. Defaults Upon Senior Securities

None.

### Item 4. Mine Safety Disclosures

Not applicable.

### Item 5. Other Information

(c) Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or may represent a "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K).

On September 15, 2025, Meredith Cook, Senior Vice President, General Counsel and Corporate Secretary, adopted a Rule 10b5-1 trading plan. Ms. Cook's Rule 10b5-1 trading plan provides for a term commencing on January 13, 2026 and ending on December 31, 2026 for the sale of up to 6,000 shares of common stock of the Company.

On September 18, 2025, Krista Davis, Senior Vice President and Chief Human Resources Officer, adopted a Rule 10b5-1 trading plan. Ms. Davis' Rule 10b5-1 trading plan provides for a term commencing on December 18, 2025 and ending on November 4, 2026 and for the sale of up to (i) 1,622 shares of the common stock of the Company, (ii) up to 17,541 shares of common stock upon the vesting of certain RSAs, subject to reduction for shares withheld by the Company to satisfy tax withholding obligations and (iii) up to 4,052 shares of common stock upon the vesting of certain PSUs, subject to the satisfaction of certain performance conditions and reduction for shares withheld by the Company to satisfy tax withholding obligations.

## Item 6. Exhibits

The exhibits listed in the Index to Exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q.

### INDEX TO EXHIBITS

<b>Exhibit No.</b>	<b>Description</b>
10.1	<a href="#">Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Stephen P. Carey.</a>
10.2	<a href="#">Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Meredith Cook.</a>
10.3	<a href="#">Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Krista Davis.</a>
10.4	<a href="#">Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Chad Gassert.</a>
10.5	<a href="#">Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Ori Gutweg.</a>
10.6	<a href="#">Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Nikhil Lalwani.</a>
10.7	<a href="#">Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Christopher Mutz.</a>
10.8	<a href="#">Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Muthusamy Shanmugam.</a>
31.1	<a href="#">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a).</a>
31.2	<a href="#">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a).</a>
32.1*	<a href="#">Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

\* In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ANI Pharmaceuticals, Inc. (Registrant)

Date: November 7, 2025

By: /s/ Nikhil Lalwani  
Nikhil Lalwani  
President and  
Chief Executive Officer  
(principal executive officer)

Date: November 7, 2025

By: /s/ Stephen P. Carey  
Stephen P. Carey  
Senior Vice President, Finance and  
Chief Financial Officer  
(principal financial and accounting officer)

**AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT**

This Amendment No. 1 (this "Amendment") to Executive Employment Agreement, dated as of January 17, 2020 (the "Prior Agreement"), is made and entered into as of October 27, 2025 (the "Effective Date"), by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and Stephen P. Carey. Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Prior Agreement.

**RECITALS**

**WHEREAS**, the parties hereto are parties to the Prior Agreement; and

**WHEREAS**, the parties hereto desire to amend certain provisions of the Prior Agreement.

**AGREEMENT**

**NOW, THEREFORE**, in consideration of the foregoing, the premises and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **Amendments.**

1.1 Amendment to Section 3(e)(i)(C). Section 3(e)(i)(C) of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

“(C) Executive shall be paid a pro-rated Incentive Bonus for the fiscal year during which Executive’s employment is terminated (prorated based on the days elapsed in such fiscal year through the Termination Date);”

1.2 New Section 8(a)(vii). A new Section 8(a)(vii) is hereby added to the Prior Agreement, to read as follows:

2. “(vii) To the extent that Executive’s Termination Date is prior to the payment of the Executive’s annual Incentive Bonus for work performed in the year prior to the Termination Date, the Company will pay the Executive the Incentive Bonus that Executive would have earned for such prior year based on actual performance as if Executive had remained employed until the payment of such annual Incentive Bonus.”

2.1 New Section 23. A new Section 23 is hereby added to the Prior Agreement, to read as follows:

2.2 Cooperation with Litigation. During and following the termination of Executive’s employment with the Company (regardless of the reason for Executive’s termination of employment with the Company and which Party initiates the termination of employment with the Company), Executive agrees to cooperate with and make himself readily available to the Company, the

Company's Chief Legal Officer (or equivalent position within the Company) and/or its advisers, as the Company may reasonably request, to assist it in any matter regarding the Company and its subsidiaries and parent companies, including giving truthful testimony in any litigation, potential litigation or any internal investigation or administrative, regulatory, judicial or quasi-judicial proceedings involving the Company over which Executive has knowledge, experience or information. Executive acknowledges that this could involve, but is not limited to, responding to or defending any regulatory or legal process, providing information in relation to any such process, preparing witness statements and giving evidence in person on behalf of the Company. The Company shall work with Executive to ensure that such cooperation does not unduly burden Executive; work in good faith to accommodate Executive's other commitments and reimburse any reasonable expenses incurred by Executive, including reasonable attorneys' fees and costs, as a consequence of complying with his obligations under this Section, provided that such expenses are approved in advance by the Company."

3. **Governing Law.** This Amendment and related agreements, instruments, and documents shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflicts of laws principles thereof.

4. **Incorporation and Reaffirmation.** This Amendment shall amend and is incorporated into and made part of the Prior Agreement. To the extent that any term or provision of this Amendment may be deemed expressly inconsistent with any term or provision in the Prior Agreement, the terms and provisions of this Amendment shall control. Except as expressly amended by this Amendment, all of the terms, conditions, and provisions of the Prior Agreement are hereby ratified and continue unchanged and remain in full force and effect.

5. **Entire Agreement.** Subject to Section 3 hereof, this Amendment constitutes the complete understanding of the parties hereto regarding the subject matter hereof and supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other statement or promise relating to the subject matter hereof that is not contained herein, shall be valid or binding.

6. **Binding Effect.** This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators, trustees, representatives, successors, and assigns.

7. **Execution by Counterparts and Facsimile.** This Amendment may be executed by facsimile, and in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

[Signature Page Follows]

**IN WITNESS WHEREOF**, the undersigned, intending to be legally bound, have duly executed this Amendment, as of the Effective Date.

**ANI PHARMACEUTICALS, INC.**

By:  /s/ Nikhil Lalwani

Name: Nikhil Lalwani

Title: President & CEO

**STEPHEN P. CAREY**

By:  /s/ Stephen P. Carey

**[Signature Page to Amendment]**

**AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT**

This Amendment No. 1 (this "Amendment") to Executive Employment Agreement, dated as of June 21, 2022 (the "Prior Agreement"), is made and entered into as of October 27, 2025 (the "Effective Date"), by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and Meredith Cook. Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Prior Agreement.

**RECITALS**

**WHEREAS**, the parties hereto are parties to the Prior Agreement; and

**WHEREAS**, the parties hereto desire to amend certain provisions of the Prior Agreement.

**AGREEMENT**

**NOW, THEREFORE**, in consideration of the foregoing, the premises and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **Amendments.**

1.1 Amendment to Section 3(e)(i)(C). Section 3(e)(i)(C) of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

“(C) Executive shall be paid a pro-rated Incentive Bonus for the fiscal year during which Executive’s employment is terminated (prorated based on the days elapsed in such fiscal year through the Termination Date);”

1.2 New Section 8(a)(vii). A new Section 8(a)(vii) is hereby added to the Prior Agreement, to read as follows:

2. “(vii) To the extent that Executive’s Termination Date is prior to the payment of the Executive’s annual Incentive Bonus for work performed in the year prior to the Termination Date, the Company will pay the Executive the annual Incentive Bonus that Executive would have earned for such prior year based on actual performance as if Executive had remained employed until the payment of such annual Incentive Bonus.”

2.1 Amendment to Section 19. Section 19 of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

2.2 Cooperation with Litigation. During and following the Executive’s Termination of Employment with the Company (regardless of the reason for Executive’s Termination of Employment with the Company and which Party initiates the Termination of Employment with the Company), Executive agrees to cooperate with and make herself readily available to the Company, the

Company's Chief Legal Officer (or equivalent position within the Company) and/or its advisers, as the Company may reasonably request, to assist it in any matter regarding the Company and its subsidiaries and parent companies, including giving truthful testimony in any litigation, potential litigation or any internal investigation or administrative, regulatory, judicial or quasi-judicial proceedings involving the Company over which Executive has knowledge, experience or information. Executive acknowledges that this could involve, but is not limited to, responding to or defending any regulatory or legal process, providing information in relation to any such process, preparing witness statements and giving evidence in person on behalf of the Company. The Company shall work with Executive to ensure that such cooperation does not unduly burden Executive; work in good faith to accommodate Executive's other commitments and reimburse any documented expenses incurred by Executive, including reasonable attorneys' fees and costs, as a consequence of complying with her obligations under this Section, provided that such expenses are approved in advance by the Company."

3. **Governing Law.** This Amendment and related agreements, instruments, and documents shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflicts of laws principles thereof.

4. **Incorporation and Reaffirmation.** This Amendment shall amend and is incorporated into and made part of the Prior Agreement. To the extent that any term or provision of this Amendment may be deemed expressly inconsistent with any term or provision in the Prior Agreement, the terms and provisions of this Amendment shall control. Except as expressly amended by this Amendment, all of the terms, conditions, and provisions of the Prior Agreement are hereby ratified and continue unchanged and remain in full force and effect.

5. **Entire Agreement.** Subject to Section 3 hereof, this Amendment constitutes the complete understanding of the parties hereto regarding the subject matter hereof and supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other statement or promise relating to the subject matter hereof that is not contained herein, shall be valid or binding.

6. **Binding Effect.** This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators, trustees, representatives, successors, and assigns.

7. **Execution by Counterparts and Facsimile.** This Amendment may be executed by facsimile, and in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

[Signature Page Follows]

**IN WITNESS WHEREOF**, the undersigned, intending to be legally bound, have duly executed this Amendment, as of the Effective Date.

**ANI PHARMACEUTICALS, INC.**

By:  /s/ Nikhil Lalwani

Name: Nikhil Lalwani

Title: President & CEO

**MEREDITH COOK**

By:  /s/ Meredith Cook

**[Signature Page to Amendment]**

## AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment No. 1 (this “Amendment”) to Executive Employment Agreement, dated as of July 14, 2022 (the “Prior Agreement”), is made and entered into as of October 27, 2025 (the “Effective Date”), by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Krista Davis. Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Prior Agreement.

### RECITALS

**WHEREAS**, the parties hereto are parties to the Prior Agreement; and

**WHEREAS**, the parties hereto desire to amend certain provisions of the Prior Agreement.

### AGREEMENT

**NOW, THEREFORE**, in consideration of the foregoing, the premises and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **Amendments.**

1.1 **Amendment to Section 3(e)(i)(C).** Section 3(e)(i)(C) of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

“(C) Executive shall be paid a pro-rated Incentive Bonus for the fiscal year during which Executive’s employment is terminated (prorated based on the days elapsed in such fiscal year through the Termination Date);”

2. **Governing Law.** This Amendment and related agreements, instruments, and documents shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflicts of laws principles thereof.

3. **Incorporation and Reaffirmation.** This Amendment shall amend and is incorporated into and made part of the Prior Agreement. To the extent that any term or provision of this Amendment may be deemed expressly inconsistent with any term or provision in the Prior Agreement, the terms and provisions of this Amendment shall control. Except as expressly amended by this Amendment, all of the terms, conditions, and provisions of the Prior Agreement are hereby ratified and continue unchanged and remain in full force and effect.

4. **Entire Agreement.** Subject to Section 3 hereof, this Amendment constitutes the complete understanding of the parties hereto regarding the subject matter hereof and supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other statement or promise relating to the subject matter hereof that is not contained herein, shall be valid or binding.

5. **Binding Effect.** This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators, trustees, representatives, successors, and assigns.

6. **Execution by Counterparts and Facsimile.** This Amendment may be executed by facsimile, and in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

**[Signature Page Follows]**

**IN WITNESS WHEREOF**, the undersigned, intending to be legally bound, have duly executed this Amendment, as of the Effective Date.

**ANI PHARMACEUTICALS, INC.**

By:  /s/ Nikhil Lalwani

Name: Nikhil Lalwani

Title: President & CEO

**KRISTA DAVIS**

By:  /s/ Krista Davis

**[Signature Page to Amendment]**

## AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment No. 1 (this "Amendment") to Executive Employment Agreement, dated as of March 8, 2021 (the "Prior Agreement"), is made and entered into as of October 27, 2025 (the "Effective Date"), by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and Chad Gassert. Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Prior Agreement.

### RECITALS

**WHEREAS**, the parties hereto are parties to the Prior Agreement; and

**WHEREAS**, the parties hereto desire to amend certain provisions of the Prior Agreement.

### AGREEMENT

**NOW, THEREFORE**, in consideration of the foregoing, the premises and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **Amendments.**

1.1 Amendment to Section 3(e)(i)(C). Section 3(e)(i)(C) of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

“(C) Executive shall be paid a pro-rated Incentive Bonus for the fiscal year during which Executive’s employment is terminated (prorated based on the days elapsed in such fiscal year through the Termination Date);”

1.2 Renumbering of Certain Prior Sections; New Section 3(e)(ii). Sections 3(e)(ii) and 3(e)(iii) of the Prior Agreement are hereby renumbered to Sections 3(e)(iii) and 3(e)(iv), respectively, and a new Section 3(e)(ii) is hereby added to the Prior Agreement, to read as follows:

1.3 “(ii) The amount of the Incentive Bonus payments described in clause (i)(C) shall be determined based on the maximum Incentive Bonus for such fiscal year and shall be paid to Executive when Incentive Bonus payments for the applicable fiscal year are paid to other executives of the Company.”

1.4 New Section 8(a)(vi). A new Section 8(a)(vi) is hereby added to the Prior Agreement, to read as follows:

2. “(vi) To the extent that Executive’s Termination Date is prior to the payment of the Executive’s annual Incentive Bonus for work performed in the year prior to the Termination Date, the Company will pay the Executive the annual Incentive Bonus that Executive would have earned for such prior year

based on actual performance as if Executive had remained employed until the payment of such annual Incentive Bonus.”

2.1 Amendment to Section 19. Section 19 of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

2.2 “Cooperation with Litigation. During and following the termination of Executive’s employment with the Company (regardless of the reason for Executive’s termination of employment with the Company and which Party initiates the termination of employment with the Company), Executive agrees to cooperate with and make himself readily available to the Company, the Company’s Chief Legal Officer (or equivalent position within the Company) and/or its advisers, as the Company may reasonably request, to assist it in any matter regarding the Company and its subsidiaries and parent companies, including giving truthful testimony in any litigation, potential litigation or any internal investigation or administrative, regulatory, judicial or quasi-judicial proceedings involving the Company over which Executive has knowledge, experience or information. Executive acknowledges that this could involve, but is not limited to, responding to or defending any regulatory or legal process, providing information in relation to any such process, preparing witness statements and giving evidence in person on behalf of the Company. The Company shall work with Executive to ensure that such cooperation does not unduly burden Executive; work in good faith to accommodate Executive’s other commitments and reimburse any reasonable expenses incurred by Executive, including reasonable attorneys’ fees and costs, as a consequence of complying with his obligations under this Section, provided that such expenses are approved in advance by the Company.”

3. **Governing Law.** This Amendment and related agreements, instruments, and documents shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflicts of laws principles thereof.

4. **Incorporation and Reaffirmation.** This Amendment shall amend and is incorporated into and made part of the Prior Agreement. To the extent that any term or provision of this Amendment may be deemed expressly inconsistent with any term or provision in the Prior Agreement, the terms and provisions of this Amendment shall control. Except as expressly amended by this Amendment, all of the terms, conditions, and provisions of the Prior Agreement are hereby ratified and continue unchanged and remain in full force and effect.

5. **Entire Agreement.** Subject to Section 3 hereof, this Amendment constitutes the complete understanding of the parties hereto regarding the subject matter hereof and supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other statement or promise relating to the subject matter hereof that is not contained herein, shall be valid or binding.

6. **Binding Effect.** This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators, trustees, representatives, successors, and assigns.

7. **Execution by Counterparts and Facsimile.** This Amendment may be executed by facsimile, and in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

**[Signature Page Follows]**

**IN WITNESS WHEREOF**, the undersigned, intending to be legally bound, have duly executed this Amendment, as of the Effective Date.

**ANI PHARMACEUTICALS, INC.**

By:  /s/ Nikhil Lalwani

Name: Nikhil Lalwani

Title: President & CEO

**CHAD GASSERT**

By:  /s/ Chad Gassert

**[Signature Page to Amendment]**

## AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment No. 1 (this “Amendment”) to Executive Employment Agreement, dated as of January 18, 2021 (the “Prior Agreement”), is made and entered into as of October 27, 2025 (the “Effective Date”), by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Ori Gutwerg. Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Prior Agreement.

### RECITALS

**WHEREAS**, the parties hereto are parties to the Prior Agreement; and

**WHEREAS**, the parties hereto desire to amend certain provisions of the Prior Agreement.

### AGREEMENT

**NOW, THEREFORE**, in consideration of the foregoing, the premises and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **Amendments.**

1.1 Amendment to Section 3(e)(i)(C). Section 3(e)(i)(C) of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

“(C) Executive shall be paid a pro-rated Incentive Bonus for the fiscal year during which Executive’s employment is terminated (prorated based on the days elapsed in such fiscal year through the Termination Date);”

1.2 New Section 8(a)(vii). A new Section 8(a)(vii) is hereby added to the Prior Agreement, to read as follows:

2. “(vii) To the extent that Executive’s Termination Date is prior to the payment of the Executive’s annual Incentive Bonus for work performed in the year prior to the Termination Date, the Company will pay the Executive the annual Incentive Bonus that Executive would have earned for such prior year based on actual performance as if Executive had remained employed until the payment of such annual Incentive Bonus.”

2.1 New Section 24. A new Section 24 is hereby added to the Prior Agreement, to read as follows:

2.2 “Cooperation with Litigation. During and following the termination of Executive’s employment with the Company (regardless of the reason for Executive’s termination of employment with the Company and which

Party initiates the termination of employment with the Company), Executive agrees to cooperate with and make himself readily available to the Company, the Company's Chief Legal Officer (or equivalent position within the Company) and/or its advisers, as the Company may reasonably request, to assist it in any matter regarding the Company and its subsidiaries and parent companies, including giving truthful testimony in any litigation, potential litigation or any internal investigation or administrative, regulatory, judicial or quasi-judicial proceedings involving the Company over which Executive has knowledge, experience or information. Executive acknowledges that this could involve, but is not limited to, responding to or defending any regulatory or legal process, providing information in relation to any such process, preparing witness statements and giving evidence in person on behalf of the Company. The Company shall work with Executive to ensure that such cooperation does not unduly burden Executive; work in good faith to accommodate Executive's other commitments and reimburse any reasonable expenses incurred by Executive, including reasonable attorneys' fees and costs, as a consequence of complying with his obligations under this Section, provided that such expenses are approved in advance by the Company."

3. **Governing Law.** This Amendment and related agreements, instruments, and documents shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflicts of laws principles thereof.

4. **Incorporation and Reaffirmation.** This Amendment shall amend and is incorporated into and made part of the Prior Agreement. To the extent that any term or provision of this Amendment may be deemed expressly inconsistent with any term or provision in the Prior Agreement, the terms and provisions of this Amendment shall control. Except as expressly amended by this Amendment, all of the terms, conditions, and provisions of the Prior Agreement are hereby ratified and continue unchanged and remain in full force and effect.

5. **Entire Agreement.** Subject to Section 3 hereof, this Amendment constitutes the complete understanding of the parties hereto regarding the subject matter hereof and supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other statement or promise relating to the subject matter hereof that is not contained herein, shall be valid or binding.

6. **Binding Effect.** This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators, trustees, representatives, successors, and assigns.

7. **Execution by Counterparts and Facsimile.** This Amendment may be executed by facsimile, and in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

[Signature Page Follows]

**IN WITNESS WHEREOF**, the undersigned, intending to be legally bound, have duly executed this Amendment, as of the Effective Date.

**ANI PHARMACEUTICALS, INC.**

By:  /s/ Nikhil Lalwani

Name: Nikhil Lalwani

Title: President & CEO

**ORI GUTWERG**

By:  /s/ Ori Gutwerg

**[Signature Page to Amendment]**

## AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment No. 1 (this “Amendment”) to Executive Employment Agreement, dated as of July 24, 2020 (the “Prior Agreement”), is made and entered into as of October 27, 2025 (the “Effective Date”), by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Nikhil Lalwani. Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Prior Agreement.

### RECITALS

**WHEREAS**, the parties hereto are parties to the Prior Agreement; and

**WHEREAS**, the parties hereto desire to amend certain provisions of the Prior Agreement.

### AGREEMENT

**NOW, THEREFORE**, in consideration of the foregoing, the premises and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **Amendments.**

1.1 Amendment to Section 3(e)(i)(C). Section 3(e)(i)(C) of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

“(C) Executive shall be paid a pro-rated Incentive Bonus for the fiscal year during which Executive’s employment is terminated (prorated based on the days elapsed in such fiscal year through the Termination Date);”

1.2 New Section 8(a)(viii). A new Section 8(a)(viii) is hereby added to the Prior Agreement, to read as follows:

“(viii) To the extent that Executive’s Termination Date is prior to the payment of the Executive’s annual Incentive Bonus for work performed in the year prior to the Termination Date, the Company will pay the Executive the annual Incentive Bonus that Executive would have earned for such prior year based on actual performance as if Executive had remained employed until the payment of such annual Incentive Bonus.”

2.1 New Section 24. A new Section 24 is hereby added to the Prior Agreement, to read as follows:

2.2 “Cooperation with Litigation. During and following the termination of Executive’s employment with the Company (regardless of the reason for Executive’s termination of employment with the Company and which Party initiates the termination of employment with the Company), Executive agrees to cooperate with and make himself readily available to the Company, the

Company's Chief Legal Officer (or equivalent position within the Company) and/or its advisers, as the Company may reasonably request, to assist it in any matter regarding the Company and its subsidiaries and parent companies, including giving truthful testimony in any litigation, potential litigation or any internal investigation or administrative, regulatory, judicial or quasi-judicial proceedings involving the Company over which Executive has knowledge, experience or information. Executive acknowledges that this could involve, but is not limited to, responding to or defending any regulatory or legal process, providing information in relation to any such process, preparing witness statements and giving evidence in person on behalf of the Company. The Company shall work with Executive to ensure that such cooperation does not unduly burden Executive; work in good faith to accommodate Executive's other commitments and reimburse any reasonable expenses incurred by Executive, including reasonable and documented attorneys' fees and costs, as a consequence of complying with his obligations under this Section, provided that such expenses are approved in advance by the Company."

3. **Governing Law.** This Amendment and related agreements, instruments, and documents shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflicts of laws principles thereof.

4. **Incorporation and Reaffirmation.** This Amendment shall amend and is incorporated into and made part of the Prior Agreement. To the extent that any term or provision of this Amendment may be deemed expressly inconsistent with any term or provision in the Prior Agreement, the terms and provisions of this Amendment shall control. Except as expressly amended by this Amendment, all of the terms, conditions, and provisions of the Prior Agreement are hereby ratified and continue unchanged and remain in full force and effect.

5. **Entire Agreement.** Subject to Section 3 hereof, this Amendment constitutes the complete understanding of the parties hereto regarding the subject matter hereof and supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other statement or promise relating to the subject matter hereof that is not contained herein, shall be valid or binding.

6. **Binding Effect.** This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators, trustees, representatives, successors, and assigns.

7. **Execution by Counterparts and Facsimile.** This Amendment may be executed by facsimile, and in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

[Signature Page Follows]

**IN WITNESS WHEREOF**, the undersigned, intending to be legally bound, have duly executed this Amendment, as of the Effective Date.

**ANI PHARMACEUTICALS, INC.**

By:   /s/ Stephen P. Carey  \_\_\_\_\_

Name: Stephen P. Carey

Title: Chief Financial Officer

**NIKHIL LALWANI**

By:   /s/ Nikhil Lalwani  \_\_\_\_\_

**[Signature Page to Amendment]**

## AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment No. 1 (this “Amendment”) to Executive Employment Agreement, dated as of February 10, 2021 (the “Prior Agreement”), is made and entered into as of October 27, 2025 (the “Effective Date”), by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Christopher Mutz. Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Prior Agreement.

### RECITALS

**WHEREAS**, the parties hereto are parties to the Prior Agreement; and

**WHEREAS**, the parties hereto desire to amend certain provisions of the Prior Agreement.

### AGREEMENT

**NOW, THEREFORE**, in consideration of the foregoing, the premises and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **Amendments.**

1.1 Amendment to Section 3(e)(i)(C). Section 3(e)(i)(C) of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

“(C) Executive shall be paid a pro-rated Incentive Bonus for the fiscal year during which Executive’s employment is terminated (prorated based on the days elapsed in such fiscal year through the Termination Date);”

1.2 New Section 8(a)(vii). A new Section 8(a)(vii) is hereby added to the Prior Agreement, to read as follows:

2. “(vii) To the extent that Executive’s Termination Date is prior to the payment of the Executive’s annual Incentive Bonus for work performed in the year prior to the Termination Date, the Company will pay the Executive the annual Incentive Bonus that Executive would have earned for such prior year based on actual performance as if Executive had remained employed until the payment of such annual Incentive Bonus.”

2.1 New Section 24. A new Section 24 is hereby added to the Prior Agreement, to read as follows:

2.2 “Cooperation with Litigation. During and following the termination of Executive’s employment with the Company (regardless of the reason for Executive’s termination of employment with the Company and which Party initiates the termination of employment with the Company), Executive agrees to cooperate with and make himself readily available to the Company, the

Company's Chief Legal Officer (or equivalent position within the Company) and/or its advisers, as the Company may reasonably request, to assist it in any matter regarding the Company and its subsidiaries and parent companies, including giving truthful testimony in any litigation, potential litigation or any internal investigation or administrative, regulatory, judicial or quasi-judicial proceedings involving the Company over which Executive has knowledge, experience or information. Executive acknowledges that this could involve, but is not limited to, responding to or defending any regulatory or legal process, providing information in relation to any such process, preparing witness statements and giving evidence in person on behalf of the Company. The Company shall work with Executive to ensure that such cooperation does not unduly burden Executive; work in good faith to accommodate Executive's other commitments and reimburse any reasonable expenses incurred by Executive, including reasonable attorneys' fees and costs, as a consequence of complying with his obligations under this Section, provided that such expenses are approved in advance by the Company."

3. **Governing Law.** This Amendment and related agreements, instruments, and documents shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflicts of laws principles thereof.

4. **Incorporation and Reaffirmation.** This Amendment shall amend and is incorporated into and made part of the Prior Agreement. To the extent that any term or provision of this Amendment may be deemed expressly inconsistent with any term or provision in the Prior Agreement, the terms and provisions of this Amendment shall control. Except as expressly amended by this Amendment, all of the terms, conditions, and provisions of the Prior Agreement are hereby ratified and continue unchanged and remain in full force and effect.

5. **Entire Agreement.** Subject to Section 3 hereof, this Amendment constitutes the complete understanding of the parties hereto regarding the subject matter hereof and supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other statement or promise relating to the subject matter hereof that is not contained herein, shall be valid or binding.

6. **Binding Effect.** This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators, trustees, representatives, successors, and assigns.

7. **Execution by Counterparts and Facsimile.** This Amendment may be executed by facsimile, and in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

[Signature Page Follows]

**IN WITNESS WHEREOF**, the undersigned, intending to be legally bound, have duly executed this Amendment, as of the Effective Date.

**ANI PHARMACEUTICALS, INC.**

By:   /s/ Nikhil Lalwani  

Name: Nikhil Lalwani

Title: President & CEO

**CHRISTOPHER MUTZ**

By:   /s/ Christopher Mutz  

**[Signature Page to Amendment]**

## AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment No. 1 (this “Amendment”) to Executive Employment Agreement, dated as of March 8, 2021 (the “Prior Agreement”), is made and entered into as of October 27, 2025 (the “Effective Date”), by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Muthusamy Shanmugam. Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Prior Agreement.

### RECITALS

**WHEREAS**, the parties hereto are parties to the Prior Agreement; and

**WHEREAS**, the parties hereto desire to amend certain provisions of the Prior Agreement.

### AGREEMENT

**NOW, THEREFORE**, in consideration of the foregoing, the premises and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **Amendments.**

1.1 Amendment to Section 3(e)(i)(C). Section 3(e)(i)(C) of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

“(C) Executive shall be paid a pro-rated Incentive Bonus for the fiscal year during which Executive’s employment is terminated (prorated based on the days elapsed in such fiscal year through the Termination Date);”

1.2 Renumbering of Certain Prior Sections; New Section 3(e)(ii). Sections 3(e)(ii) and 3(e)(iii) of the Prior Agreement are hereby renumbered to Sections 3(e)(iii) and 3(e)(iv), respectively, and a new Section 3(e)(ii) is hereby added to the Prior Agreement, to read as follows:

“(ii) The amount of the Incentive Bonus payments described in clause (i)(C) shall be determined based on the maximum Incentive Bonus for such fiscal year and shall be paid to Executive when Incentive Bonus payments for the applicable fiscal year are paid to other executives of the Company.”

1.2 New Section 8(a)(vi). A new Section 8(a)(vi) is hereby added to the Prior Agreement, to read as follows:

2. “(vi) To the extent that Executive’s Termination Date is prior to the payment of the Executive’s annual Incentive Bonus for work performed in the year prior to the Termination Date, the Company will pay the Executive the annual Incentive Bonus that Executive would have earned for such prior year

based on actual performance as if Executive had remained employed until the payment of such annual Incentive Bonus.”

2.1 Amendment to Section 19. Section 19 of the Prior Agreement is hereby amended and restated in its entirety to read as follows:

2.2 “Cooperation with Litigation. During and following the termination of Executive’s employment with the Company (regardless of the reason for Executive’s termination of employment with the Company and which Party initiates the termination of employment with the Company), Executive agrees to cooperate with and make himself readily available to the Company, the Company’s Chief Legal Officer (or equivalent position within the Company) and/or its advisers, as the Company may reasonably request, to assist it in any matter regarding the Company and its subsidiaries and parent companies, including giving truthful testimony in any litigation, potential litigation or any internal investigation or administrative, regulatory, judicial or quasi-judicial proceedings involving the Company over which Executive has knowledge, experience or information. Executive acknowledges that this could involve, but is not limited to, responding to or defending any regulatory or legal process, providing information in relation to any such process, preparing witness statements and giving evidence in person on behalf of the Company. The Company shall work with Executive to ensure that such cooperation does not unduly burden Executive; work in good faith to accommodate Executive’s other commitments and reimburse any reasonable expenses incurred by Executive, including reasonable attorneys’ fees and costs, as a consequence of complying with his obligations under this Section, provided that such expenses are approved in advance by the Company.”

3. **Governing Law.** This Amendment and related agreements, instruments, and documents shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflicts of laws principles thereof.

4. **Incorporation and Reaffirmation.** This Amendment shall amend and is incorporated into and made part of the Prior Agreement. To the extent that any term or provision of this Amendment may be deemed expressly inconsistent with any term or provision in the Prior Agreement, the terms and provisions of this Amendment shall control. Except as expressly amended by this Amendment, all of the terms, conditions, and provisions of the Prior Agreement are hereby ratified and continue unchanged and remain in full force and effect.

5. **Entire Agreement.** Subject to Section 3 hereof, this Amendment constitutes the complete understanding of the parties hereto regarding the subject matter hereof and supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other statement or promise relating to the subject matter hereof that is not contained herein, shall be valid or binding.

6. **Binding Effect.** This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators, trustees, representatives, successors, and assigns.

7. **Execution by Counterparts and Facsimile.** This Amendment may be executed by facsimile, and in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

**[Signature Page Follows]**

**IN WITNESS WHEREOF**, the undersigned, intending to be legally bound, have duly executed this Amendment, as of the Effective Date.

**ANI PHARMACEUTICALS, INC.**

By:  /s/ Nikhil Lalwani

Name: Nikhil Lalwani

Title: President & CEO

**MUTHUSAMY SHANMUGAM**

By:  /s/ Muthusamy Shanmugam

**[Signature Page to Amendment]**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Nikhil Lalwani, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ANI Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 7, 2025

/s/ Nikhil Lalwani

---

Nikhil Lalwani  
President and  
Chief Executive Officer  
(principal executive officer)

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Stephen P. Carey, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ANI Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 7, 2025

/s/ Stephen P. Carey

---

Stephen P. Carey

Senior Vice President, Finance and Chief Financial Officer  
(principal financial and accounting officer)

**CERTIFICATION  
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED  
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report on Form 10-Q of ANI Pharmaceuticals, Inc. (the "Company") for the quarterly period ended September 30, 2025 (the "Report") as filed with the Securities and Exchange Commission on the date hereof, the undersigned Chief Executive Officer and Chief Financial Officer of the Company hereby certify that, to such officer's knowledge:

- (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is provided solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Dated: November 7, 2025

/s/ Nikhil Lalwani

---

Nikhil Lalwani  
President and Chief Executive Officer  
(principal executive officer)

Dated: November 7, 2025

/s/ Stephen P. Carey

---

Stephen P. Carey  
Senior Vice President, Finance and Chief Financial Officer  
(principal financial and accounting officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.